  A Phase 1 Clinical Trial  to Evaluate the Plasma Pharmacokinetics,  Safety, 
and Tolerability  of a Single Oral Dose of Zoliflodacin in Healthy Male and 
Female Subjects 
 
DMID Protocol Number: 16-0118 
 
 
DMID Funding Mechanism:  Phase 1 Clinical Trial Unit  
 
 
Pharmaceutical Support  Provided by:  [CONTACT_707761]:  Division of Microbiology and Infectious Diseases, National 
Institute of Allergy and Infectious Diseases, National Institutes of Health  
 
 
Site Principal I nvestigator: Barbara Lomeli , MD 
 
 
DMID Clinical Project Manager: Meg Gordon, RN  
 
 
DMID Medical Officer: Rick Fairhurst, MD, PhD  
 
 
DMID Medical Monitor: Soju Chang , MD 
 
 
Version Number: 2.0 
 
 
25 January 2018 
 
 
DMID Protocol 16 -0118 Version 2.0 
Zoliflodacin  25 January 2018  
 ________________________________ ________________________________ ________________________________ ______  
2 STATEMENT OF COMPLIA NCE 
The trial will be carried out in accordance with Good Clinical Practice (GCP) as required by:  
• [LOCATION_002] Code of Federal Regulations (CFR) applicable to clinical trials (45 CFR Part 
46, 21 CFR Part 50, 21 CFR Part 54, 21 CFR Part 56, and 21 CFR Part 312);  
• International Conference on Harmonization (ICH) E6; 62 Federal Register [ZIP_CODE] (1997); 
• National Institutes of Health (NIH) Clinical Terms of Award, as applicable.  
Compliance with these s tandards provides public assurance that the rights, safety , and well-being 
of study subjects are protected, consistent with the principles that have their origin in the 
Declaration of Helsinki.  
All key personnel (all individuals responsible for the design and conduct of th e trial) have 
completed Human Subjects Protection Training.   
DMID Protocol 16 -0118 Version 2.0 
Zoliflodacin  25 January 2018  
 ________________________________ ________________________________ ________________________________ ______  
3 SIGNATURE [CONTACT_707792] e protocol and its attachments, and  provides 
the necessary assurances that th e trial will be conducted according to all stipulations of the 
protocol, including all statements regarding confidentiality, and according to local legal and 
regulatory requirements and applicable [LOCATION_002] of America (US) federal regulations and 
ICH guidelines.  
 
 
 
Site Investigator:   
 
__________________________________ _______________  
Name/Title (Print)  
 
 
Signature:   
____________________ ______________ _______________  
 
Date:   
_________________________________________________  
 
 
 
 
  
DMID Protocol 16 -0118 Version 2.0 
Zoliflodacin  25 January 2018  
 ________________________________ ________________________________ ________________________________ ______  
4 TABLE OF CONTENTS  
  Page 
1 Key Roles  ................................ ................................ ................................ .............................. 15 
2 Background Information and Scientific Rationale  ................................ ............................... 18 
2.1 Background Information  ................................ ................................ ........................... 18 
2.1.1 Overview of the Disease: Gonorrhea and its Treatment  ............................... [ADDRESS_961666] to Follow -up ................................ ................................ .......................... 33 
5.3.6 Termination of Study  ................................ ................................ .................... 33 
6 Study Intervention/investigational product  ................................ ................................ ...........[ADDRESS_961667] Storage and Stability ................................ ................................ ........34 
6.2 Dosage, Preparation, and Administration of Study Intervention/ Investigational 
Product ................................ ................................ ................................ ...................... 35 
6.3 Modification of Study Intervention/Investigational Product for a Subject  ...............35 
6.3.1 Overdose  ................................ ................................ ................................ .......36 
6.4 Accountability Procedures for the Study Intervention/Investigational Product(s)  ...[ADDRESS_961668] Compliance with Study Intervention/ Investigational 
Product/Device  ................................ ................................ ................................ ..........36 
6.6 Prior and  Concomitant Medications/Treatments  ................................ ..................... [ADDRESS_961669] Restrictions  ................................ ................................ ................................ ..37 
6.7.1 Physical Activity  ................................ ................................ ........................... 37 
6.7.2 Fluid and Food intake  ................................ ................................ ................... 38 
6.7.3  Alcohol, Marijuana and Illicit Drugs  ................................ ............................ 38 
6.7.4 Other Restrictions  ................................ ................................ ......................... 38 
7 Study Schedule  ................................ ................................ ................................ ..................... 39 
7.1 Recruitment  ................................ ................................ ................................ ...............39 
7.2 Screening Visit (Day -21 to Day -2) ................................ ................................ .........39 
7.3 Enrollment/Baseline  ................................ ................................ ................................ ..40 
7.3.1 Admission Visit (Day -1, Unit Check -in) ................................ ..................... 40 
7.4 Inpatient period (Days 1 to 4)  ................................ ................................ ................... 40 
7.4.1 Administration of Study Drug (Day 1)  ................................ ......................... 40 
7.4.2 In-patient Follow -up Day 2 ................................ ................................ ...........41 
7.4.3 In-patient Follow -up Day 3 ................................ ................................ ...........41 
7.4.4 Discharge from Unit (Day 4)  ................................ ................................ ........42 
7.5 Final Study Visit (Day 8 ± 2)  ................................ ................................ .................... 42 
7.6 Early Termination Visit (if needed)  ................................ ................................ ..........43 
7.7 Unscheduled Visit (if needed)  ................................ ................................ .................. 43 
8 Study Procedures/evaluations  ................................ ................................ ............................... 44 
8.1 Clinical Procedures/Evaluations  ................................ ................................ ...............44 
8.1.1 Informed Consent ................................ ................................ .......................... 44 
8.1.2 Demographics  ................................ ................................ ............................... 44 
8.1.3 Inclusion/Exclusion Criteria  ................................ ................................ .........44 
8.1.4 Medical History  ................................ ................................ ............................ 44 
8.1.5 Physical Examination ................................ ................................ .................... 45 
8.1.6 Vital Signs  ................................ ................................ ................................ .....45 
8.1.7 Electrocardiogram  ................................ ................................ ......................... 46 
8.2 Laboratory Evaluations  ................................ ................................ ............................. 46 
8.2.1 Clinical Laboratory Evaluations  ................................ ................................ ...46 
DMID Protocol 16 -0118 Version 2.0 
Zoliflodacin  25 January 2018  
 ________________________________ ________________________________ ________________________________ ______  
6 [IP_ADDRESS] Screening and Safety Clinical Laboratory (Hematolo gy, Chemistry, 
and Urinalysis) Tests ................................ ................................ .........46 
[IP_ADDRESS] Viral Serology Testing  ................................ ................................ ......47 
[IP_ADDRESS] Pregnancy Testing  ................................ ................................ .............47 
[IP_ADDRESS] Serum FSH testing  ................................ ................................ ............47 
[IP_ADDRESS] Urine Toxicology Screening  ................................ ............................. 47 
[IP_ADDRESS] Alcohol testing by [CONTACT_27473]  ................................ ........................ 48 
8.2.2 Special Assays or Procedures  ................................ ................................ .......48 
[IP_ADDRESS] Pharmacokinetics Assay of Zoliflodacin  ................................ ..........48 
8.2.3 Specimen Preparation, Handling, and Shippi[INVESTIGATOR_007]  ................................ ...........48 
[IP_ADDRESS] Instructions for Specimens Preparation, Handling, and Storage  ......48 
[IP_ADDRESS] Specimen Shipment  ................................ ................................ ..........48 
9 Assessment of Safety  ................................ ................................ ................................ ............50 
9.1 Specification of Safety Parameters  ................................ ................................ ...........50 
9.2 Methods and Timing for Assessing, Recording, and Analyzing Safety 
Parameters  ................................ ................................ ................................ ................. 50 
9.2.1 Adverse Events  ................................ ................................ ............................. 50 
[IP_ADDRESS] Severity of Events  ................................ ................................ .............51 
[IP_ADDRESS] Relationship to Study Products  ................................ ......................... 51 
[IP_ADDRESS] Reporting Adverse Events  ................................ ................................ 51 
9.2.2 Reactogenicity (for Vaccine Studies and Some Therapeutic Trials)  ............[ADDRESS_961670] 
Values or Abnormal Clinical Findings  ................................ ......................... 52 
9.3 Reporting Procedures  ................................ ................................ ................................ 53 
9.3.1 Serious Adverse Events  ................................ ................................ ................ 53 
9.3.2 Regulatory Reporting for Studies Conducted Under DMID Sponsored 
IND ................................ ................................ ................................ ...............54 
9.3.3 Other Adverse Ev ents (if applicable)  ................................ ............................ 55 
[IP_ADDRESS] Reporting of Overdose  ................................ ................................ ......55 
9.3.4 Reporting of Pregnancy  ................................ ................................ ................ 55 
9.4 Type and Duration of Follow -up of Subjects after Adverse Events  ......................... 55 
9.5 Halting Rules  ................................ ................................ ................................ ............56 
9.5.1 Study Halting Criteria  ................................ ................................ ................... 56 
9.6 Safety Oversight (ISM plus SMC)  ................................ ................................ ............56 
9.6.1 Independent Safety Monitor (ISM)  ................................ ............................... 56 
9.6.2 Safety Monitoring Committee (SMC)  ................................ .......................... 56 
10 Clinical Monitoring ................................ ................................ ................................ ...............58 
10.1 Site Monitoring Plan  ................................ ................................ ................................ .58 
DMID Protocol 16 -0118 Version 2.0 
Zoliflodacin  25 January 2018  
 ________________________________ ________________________________ ________________________________ ______  
7 11 Statistical Considerations  ................................ ................................ ................................ ......59 
11.1 Study Hypotheses ................................ ................................ ................................ ......59 
11.1.1 Study Objectives and Outcome Measures  ................................ .................... 59 
[IP_ADDRESS] Study Objectives  ................................ ................................ ...............59 
[IP_ADDRESS] Study Outcome Measures  ................................ ................................ .59 
11.2 Sample Size Considerations  ................................ ................................ ...................... 60 
11.3 Safety Review  ................................ ................................ ................................ ...........60 
11.4 Final Analysis Plan  ................................ ................................ ................................ ...60 
11.4.1 Analysis Populations  ................................ ................................ ..................... 60 
11.4.2 Demographics and Baseline Characteristics  ................................ ................. 61 
11.4.3 Safety Analysis Plan  ................................ ................................ ..................... 61 
[IP_ADDRESS] Adverse and Serious Adverse Events  ................................ ...............61 
[IP_ADDRESS] Additional Safety Analyses ................................ ............................... 61 
11.4.4 PK Analysis Plan  ................................ ................................ .......................... 61 
11.4.5 Missing Values and Outliers  ................................ ................................ .........62 
12 Source Documents and Access to Source Data/Documents  ................................ ................. 63 
13 Quality Control and Quality Assurance  ................................ ................................ ................ 64 
14 Ethics/Protection of Human Subjects  ................................ ................................ ................... [ADDRESS_961671]  ................................ ................................ ....................... 65 
14.3 Informed Consent Process  ................................ ................................ ........................ 65 
14.4 Exclusion of Women, Minorities, and Children (Special Populations)  .................... [ADDRESS_961672] Keepi[INVESTIGATOR_007]  ................................ ................................ ..................... 69 
15.1 Data Management Responsibilities ................................ ................................ ...........69 
15.2 Data Capture Methods  ................................ ................................ .............................. 69 
15.3 Types of Data  ................................ ................................ ................................ ............69 
15.4 Timing/Reports  ................................ ................................ ................................ .........70 
15.5 Study Records Retention ................................ ................................ ........................... 70 
15.6 Protocol Deviations  ................................ ................................ ................................ ...70 
16 Publication Policy  ................................ ................................ ................................ ................. 71 
17 Literature References  ................................ ................................ ................................ ............72 
18 Appendices ................................ ................................ ................................ ............................ 74 
Appendix A: Schedule of Study Procedures ad Evaluations  ................................ ................................ .75 
Appendix B: Acceptable Ranges of Screening Laboratory and Vital Sign Measurements  ...................... 77 
Appendix C: Adverse Events Toxicity Grading Criteria  ................................ ................................ ......81 
Appendix D: Blood Volume withdrawn during the Trial  ................................ ................................ .....[ADDRESS_961673] Aspartate aminotransferase  
AUC Area Under the Curve  
BMI Body Mass Index  
BP Blood Pressure  
bpm Beats per Minute  
BUN Blood Urea Nitrogen  
CBC Complete Blood Count  
CDC Centers for Disease Control and Prevention  
CFR Code of Federal Regulations  
Cmax Maximum Plasma Concentration  
CMS Clinical Materials Services  
ConMed(s)  Concomitant  Medication(s)  
CPM Clinical Project Manager  
CROMS Clinical Research Operations and Management Support  
CSR Clinical Study Report  
CTU Clinical Trial Unit  
CV% Coefficient of Variation  
DCC Data Coordinating Center 
DMID Division of Microbiology and Infectious Diseases  
DNA Deoxyribonucleic acid  
eCRF Electronic Case Report Form  
EC Ethics Committee  
ECG  Electrocardiogram  
EDC Electronic Data Capture  
ET Early Termination  
DMID Protocol 16 -0118 Version 2.0 
Zoliflodacin  25 January 2018  
 ________________________________ ________________________________ ________________________________ ______  
9 FDA Food and Drug Administration  
FSH Follicle-stimulating hormone  
FWA Federalwide Assurance  
g Gram(s) 
GCP Good Clinical Practice  
g/dL Gram(s) per Deciliter  
h Hour(s) 
HBsAg Hepatitis B Surface Antigen  
HCG (β-HCG) Human Chorionic Gonadotropic Hormone  
Hct Hematocrit  
Hgb Hemoglobin  
HCV Hepatitis C Virus  
HEENT Head, Eyes, Ears, Nose , and Throat  
HIV Human Immunodeficiency Virus  
HPLC-MS/MS High-Performance Liquid Chromatography with Tandem Mass 
Spectrometry   
HR Heart Rate  
IB Investigator ’s Brochure 
IC50 50% Inhibitory Concentration  
ICF Informed Consent Form  
ICH International Conference on Harmoni zation 
ICMJE International Committee of Medical Journal Editors  
IM Intramuscular  
IND Investigational New Drug  
IRB Institutional Review Board  
ISM Independent Safety Monitor  
IV Intravenous  
kg Kilogram  
LLN Lower Limit of Normal  
MDMA 3,4-methylenedioxy -methamphetamine  
MedDRA Medical Dictionary for Regulatory Activities  
DMID Protocol 16 -0118 Version 2.0 
Zoliflodacin  25 January 2018  
 ________________________________ ________________________________ ________________________________ ______  
10 MH Medical History  
µg Microgram (s) 
µM Micromolar  
µmol Micromole(s)  
mg Milligram (s) 
mg/dl Milligram (s) per Deciliter  
MIC Minimum Inhibitory Concentration  
mL Milliliter(s) 
mm Millimeter (s) 
MM Medical monitor  
MMA Mouse Micronucleus Aberration Assay  
mmHg Millimeters of Mercury  
min Minute(s)  
MOP Manual of Procedures  
msec Milliseconds(s)  
NIAID National Institute of Allergy and Infectious Diseases  
NIH National Institutes of Health  
NOAEL No observable adverse effect level  
NSAIDs Nonsteroidal Anti -Inflammatory Drugs  
OCRR Office of Clinical Research Resources  
PD Pharmacodynamic (s) 
PE Physical Examination  
PI [INVESTIGATOR_707744] 16 -0118 Version 2.0 
Zoliflodacin  25 January 2018  
 ________________________________ ________________________________ ________________________________ ______  
11 SAP Statistical Analysis Plan  
sec Second(s)  
SMC Safety Monitoring Committee  
Tmax Time to Maximum Plasma Concentration  
TCA Tricyclic antidepressants  
UA Urinalysis  
VS Vital Signs  
ULN Upper Limit of Normal  
WBC White Blood Cell Count  
WHO World Health Organization  
 
  
DMID Protocol 16 -0118 Version 2.0 
Zoliflodacin  25 January 2018  
 ________________________________ ________________________________ ________________________________ ______  
12 PROTOCOL SUMMARY  
Title:  
A Phase 1 Clinical Trial to Evaluate the Plasma Pharmacokinetics  (PK), 
Safety, and Tolerability of a Single Oral Dose of Zoliflodacin in Healthy Male 
and Female Subjects  
Phase: 1 
Population:  Eight healthy male and female subjects aged 18 to 45 years inclusive  
Number of Sites:   
One (IQVIA Phase One Services, LLC , Overland Park, KS) 
Study Duration:   
Approximately  [ADDRESS_961674] 
Participation 
Duration :  
Up to 10 days (from dosing to final visit)  
Description of 
Agents: The study drug, zoliflodacin (also known as AZD0914 and ETX0914) , is a 
spi[INVESTIGATOR_694319] . Its chemical name [CONTACT_832] (2R,4S,4aS) -
11-fluoro-2,4-dimethyl-8-[(4S)-4-methyl-2-oxo-1,3-oxazolidin -3-yl]-1,2,4,4a-
tetrahydro -2'H,6H-spi[INVESTIGATOR_2152][1,4-oxazino[4,3 -a][1,2]oxazolo[4,5 -g]quinoline -5,5'-
pyrimidine] -2',4',6'(1'H,3'H) -trione. It is formulated as a pow der in sachets 
containing 2 g rams (g) of the active agent and inactive excipi[INVESTIGATOR_840].  
Objectives :  
Primary:  
• To evaluate the plasma PK of zoliflodacin after administration of a 
single 4-g oral dose under fasting conditions  
Secondary:  
• To evaluate the safety and tolerability of a single 4-g oral dose of 
zoliflodacin  
Outcome 
Measures:  
 
 
  
Primary:  
Cmax, Tmax, AUC (0-last), and other PK parameters  for zoliflodacin  
determined using plasma  concentrations of zoliflodacin in blood 
samples collected on Day 1 [baseline ( 30 min before dosing) and 0.5 h, 
1 h, 2 h, 3 h, 4 h, 6 h, 8 h, and 12 h after dosing ], Day 2 [24 h and 36 h 
after dosing ], Day 3 [48 h after dosing ], and Day 4 [72 h after dosing ], 
DMID Protocol 16 -0118 Version 2.0 
Zoliflodacin  25 January 2018  
 ________________________________ ________________________________ ________________________________ ______  
13  
 
 
 
 or early termination ( ET), and measured using a validated HPLC -
MS/MS method 
Secondary:  
• The occurrence  of treatment -emergent serious adverse events (SAE s) 
from administration of zoliflodacin  on Day 1 to Final Visit  (Day 8 ± 2), 
or ET 
• The occurrence of unsolicited treatment -emergent adverse events 
(AEs) from administration of zoliflodacin on Day 1 to Final Visit  (Day 
8 ± 2), or ET 
• The changes from baseline (up to 60 min before dosing) in vital signs 
(VS) following administration of zoliflodacin , as measured on Day 1 [1 
h, 2 h, and 4 h after dosing ], Days 2, 3 , and 4 [24 h, 48 h, and 72 h, 
respectively,  after dosing ], and Final Visit  (Day 8 ± 2) , or ET 
• The changes from baseline (Day -1) in clinical laboratory values 
following administration of zoliflodacin , as measured on  Day 4, or ET 
• The changes from baseline (up to 60 min before dosing) in 
electrocardiogram (ECG) parameters following administration of 
zoliflodacin , as measured on Day 1 [1 h, 2 h, and 4 h after dosing ] and 
Day 4 [72 h after dosing ], or ET 
Description of 
Study Design:   
The trial is an open-label, non-randomized  evaluation of the PK and safety 
profiles of a single [ADDRESS_961675] 4 h after 
dosing. Consumption of water is permitted during the fasting period.  All 
subjects will be dosed in the morning of Day 1 in a staggered fashion  with a 
minimum of  several minutes apart.   
 
Subjects who consent to participate will be enrolled in the trial if they meet all 
of the inclusion and none of the exclusion eligibility criteria. Laboratory 
assessments at Screening Visit will include testing for serology [human 
immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg) , and 
hepatitis C virus (HCV) ], drugs of ab use, and alcohol. Serum pregnancy 
testing will be done in all females and serum FSH levels will be measured only 
in post-menopausal females . Safety assessments at scheduled visits will 
include medical history  (MH), vital signs ( VS), physical examination  (PE), 12-
lead ECG, and clinical laboratory values includ ing complete blood count 
(CBC) with differential, comprehensive metabolic (chemistry) panel, and 
urinalysis (UA)  for blood, glucose , and protein. Treatment -emergent AEs and 
SAEs will be as sessed from the time of dosing to the end of the trial. Plasma 

DMID Protocol 16 -0118 Version 2.0 
Zoliflodacin  25 January 2018  
 ________________________________ ________________________________ ________________________________ ______  
14 for PK analysis will be collected at scheduled time  points before and after 
dosing on Day 1 and through Day 4, or ET. 
Estimated Time 
to Complete 
Enrollment:  Up to 10 days (from dosing to last visit) 
Halting Criteria  
Decision Process :  
If criteria for halting the trial (as listed in Section 9.5.1) are met during dosing 
on Day 1 prior to all subjects being dosed , an ad hoc Safety Monitoring 
Committee (SMC) meeting will be held to review all available safety data and 
to make recommendation s about the dosing of all further subjects in the trial. 
A scheduled SMC meeting will be held after all subjects complete the trial to 
review all safety data, and advise on using the 4 -g dose in a subsequent 
thorough QT c study. 
 
DMID Protocol 16 -0118 Version 2.0 
Zoliflodacin  25 January 2018  
 ________________________________ ________________________________ ________________________________ ______  
15 1 KEY ROLES  
Program Principal Investigator : [INVESTIGATOR_43269] A Saviolakis, MD, PhD  
Medical Director  
DynPort Vaccine Company, LLC  
[ADDRESS_961676]  
Frederick, MD [ZIP_CODE]  
Office: [PHONE_14749] 
Mobile:  
Email: [EMAIL_13557]  
 
Site Principal Investigator:  [INVESTIGATOR_707745] , MD 
IQVIATM 
[ADDRESS_961677] 
Overland Park , KS [ZIP_CODE] 
Office: 913 -708-6999 
Mobile:  
Email: [EMAIL_13558]  
  
DMID Clinical Project Manager:  Meg Gordon, RN  
OCRR/DMID/ NIAID/NIH 
[ADDRESS_961678], Room 7G37  
Bethesda, MD  [ZIP_CODE] 
Office: [PHONE_14456] 
Mobile:  
Email: [EMAIL_13280]  
 
DMID Medical Officer: Rick Fairhurst, MD, PhD  
OCRR/DMID/NIAID/NIH  
[ADDRESS_961679], Room 8B22  
Bethesda, MD [ZIP_CODE] -9826 
Office: 301 -761-5077 
Mobile:  
Email: [EMAIL_13559]  
 
 
 

DMID Protocol 16 -0118 Version 2.0 
Zoliflodacin  25 January 2018  
 ________________________________ ________________________________ ________________________________ ______  
16   
DMID Medical Monitor:  Soju Chang, MD  
OCRR/DMID/NIAID/NIH  
[ADDRESS_961680], Room 7E59  
Bethesda, MD  [ZIP_CODE] 
Office: 240 -292-4178 
Email: [EMAIL_10075]  
 
Pharmaceutical Sponsor  
Medical Monitor : 
 Robin Isaacs,  MD 
Chief Medical Officer  
Entasis Therapeutics  
 
 
  
 
 
Safety and Pharmacovigilance 
Contractor:  Pharmacovigilance Group  
CROMS/DMID/NIAID/NIH  
[ADDRESS_961681]  
Bethesda, MD [ZIP_CODE]  
SAE Hot Line: 1 -[PHONE_889] 
SAE Fax: [PHONE_2620] 
SAE Email: [EMAIL_1393]  
 
Data Coordinating Center: The Emmes Corporation  
[ADDRESS_961682]  
Rockville, MD  [ZIP_CODE] 
Phone: 301 -251-1161 
Fax: [PHONE_9814] 
Email: [EMAIL_8999]  
 

DMID Protocol 16 -0118 Version 2.0 
Zoliflodacin  25 January 2018  
 ________________________________ ________________________________ ________________________________ ______  
17 Study Agent Repository:  Fisher BioServices  
c/o DMID Clinical Materials Services (CMS)  
[ADDRESS_961683]  
Germantown, MD [ZIP_CODE]  
Phone: 240 -477-1350  
Fax: [PHONE_6137] 
Email: [EMAIL_5798]  
 
Clinical Laboratory:  IQVIA Early Clinical Development  Laboratory  
[ADDRESS_961684] 
Overland Park, KS [ZIP_CODE]  
Phone: 913 -708-6023 
Fax: [PHONE_14750] 
 
Bioanalytical Laboratory:  KCAS Bioanalytical Services  
[ADDRESS_961685]  
Shawnee, KS [ZIP_CODE]  
POC: Marsha Luna  
          Senior Manager, PBI  
Phone: 913 -248-3042 
Email: [EMAIL_13282]  
  
DMID Protocol 16 -0118 Version 2.0 
Zoliflodacin  25 January 2018  
 ________________________________ ________________________________ ________________________________ ______  
18 2 BACKGROUND INFORMATI ON AND SCIENTIFIC 
RATIONALE  
2.1 Background Information  
2.1.1 Overview of the Disease: Gonorrhea and its Treatment  
Neisseria gonorrhoeae , currently the second  most common bacterial sexually transmitted 
infection w orldwide (after Chlamydia trachomatis ), is a serious public health problem.1,2 In 
2008, the World Health Organization (WHO) estimated 106 million cases of gonorrhea among 
adults worldwide .3 In 2012, the Centers for Disease Control and Prevention (CDC) reported  
311,404 cases of gonorrhea  in the US ; however,  due to incomplete reporting, up to 820,000 cases 
may occur annually.4 N. gonorrhoeae  has develop ed resistance to all antimicrobial treatment s for 
gonorrhea. The CDC recently released its report “Antibiotic Resistance Threats in the US, 2013 ,” 
which ranks drug -resistant N. gonorrhoeae  as an “Urgent Threat ,” defined as “an immediate 
public health threat that requires urgent and aggressive action .”[ADDRESS_961686] recently, N. gonorrhoeae resistance to macrolides (including 
azithromycin), cefixime , and ceftriaxone , and consequent clinical failures , have been reported. 
Since two extended-spectrum cephalosporins, ceftriaxone and cefixime, have recently been the 
only first-line option s for treating gonorrhea, resistance and treatment failures with these drugs 
are particularly concerning. It is only a matter of time before gonococci with full  resistance to 
extended-spectrum cephalosporins emerge and spread globally.7 The threat of widespread 
ceftriaxone resistance and untreatable N. gonorrhoeae  infection is real.5,6  The clinical 
development of zoliflodacin (also known as  AZD0914  and ETX0914 ) addresses the need for 
new antibiotics that c an be used alone or with other agents to treat uncomplicated  gonorrhea 
caused by  [CONTACT_68701] N. gonorrhoeae  strains that are resistant to existing antibiotics.8,[ADDRESS_961687] 
N. gonorrhoeae  strains that are  susceptible or resistant to current available therapi[INVESTIGATOR_707746], including in patients with  uncomplicated  gonorrhea. 8,9,10,11 
This section provides a summary of zoliflodacin. Nonclinical and clinical data are provided in 
more detail in the  Investigator’s Brochure  (IB). 
 
 
DMID Protocol 16 -0118 Version 2.0 
Zoliflodacin  25 January 2018  
 ________________________________ ________________________________ ________________________________ ______  
19 Chemistry  
The chemical name [CONTACT_694385] (2R,4S,4aS) -11-fluoro-2,4-dimethyl-8-[(4S)-4-methyl-2-
oxo-1,3-oxazolidin -3-yl]-1,2,4,4a-tetrahydro -2'H,6H-spi[INVESTIGATOR_2152][1,4-oxazino[4,3 -a][1,2]oxazolo[4,5 -
g] quinoline -5,5'-pyrimidine] -2',4',6'(1'H,3'H) -trione. 
Mechanism of Action  
Zoliflodacin  inhibits bacterial Type II topoisomerases, specifically bacterial gyrases. The activity 
and mode of inhibition of bacterial gyrase by [CONTACT_707762]. Zoliflodacin  stabilizes the  
, but in addition  prevents its  
 is further supported  
 N. gonorrhoeae  
resistance to .8 
Microbiological Activity  
In vitro: Zoliflodacin  has demonstrated activity in vitro against N. gonorrhoeae , including strains 
that are resistant to penicillin, ciprofloxacin, tetracycline, azithromycin, ceftriaxone , and 
cefixime. Minimum inhibitory concentration (MIC) 90 values ranged from 0.125 to 0.25 μg/mL. 
Zoliflodacin has also shown bactericidal activity at an MIC 90 of 0.25 μg/mL against C. 
trachomatis , which often co -infects patients with gonorrhea. 8,9,10  
In vivo: Mouse model of Staphylococcus aureus infection : An animal model for N. gonorrhoeae  
has not been established due to spontaneous bacterial eradication . To estimate a human 
efficacious exposure of zoliflodacin for N. gonorrhoeae , a surrogate pathogen approach , which 
utilizes pharmacokinetics/pharmacodynamics ( PK/PD) determinations from a  S. aureus 
neutropenic mouse thigh model that  correlates with human c linical efficacy , was used . In this 
model, zoliflodacin  was efficacious in vivo against clinical S. aureus isolates. The MIC values of 
zoliflodacin  against S. aureus and N. gonorrhoeae  and the clinical doses suggest that efficacy 
can be translated across pathogens based on AUC/MIC targets. From this analysis, the 
efficacious human exposure for zoliflodacin  was estimated utilizing a PK/PD target that covers a 
mean fAUC/MIC of 66 (range 4 3–98) for S. aureus in the mouse thigh model. This  target, 
combined with the MIC 90 of zoliflodacin  for N. gonorrhoeae  and the human unbound fraction 
(fu) of 17%, translated to a predicted efficacious mean AUC in humans of 49 µg*h/mL. 8,9 
In vivo: Human Phase 2 trial: Zoliflodacin was recently investigated in a multi -center, 
randomized, Phase 2 trial to assess the safety and efficacy of zoliflodacin administered orally to 
adults to treat uncomplicated urogenital gonorrhea compared to treatment with ceftriaxone 
administered intramuscularly. Subjects were randomly assigned to receive a single oral dose of 2  
g of zoliflodacin, 3  g of zoliflodacin, or a single intramuscular ( IM) dose of 500 mg of 

DMID Protocol 16 -0118 Version 2.0 
Zoliflodacin  25 January 2018  
 ________________________________ ________________________________ ________________________________ ______  
20 ceftriaxone. In the per -protocol population, microbiological cure was observed  
. 8 
Human Pharmacokinetics  
A single-center, multi -part, Phase 1 trial with an oral suspension of zoliflodacin versus placebo 
was conducted in healthy  men and women . In part A, 48 subjects received single ascending 
doses of zoliflodacin  ranging from 200 mg to 4  g, or placebo (6:2, zoliflodacin :placebo). In Part 
B, zoliflodacin  was administered in doses of 1 .5 g (N=8) and 3  g (N=10) to evaluate the effect of 
food on the PK of zoliflodacin . Zoliflodacin  was absorbed relatively quickly under fasting 
conditions , with a median T max ranging from . 
Following C max, plasma drug concentration s . The 
terminal elimination phase started at approximately , 
zoliflodacin  concentrations declined with a half -life ranging from  
. Exposures  
, suggesting  a  
. When  of zoliflodacin  was administered , a  
 was seen if the drug was  
 The Cmax  
 consistent with .8 
In a Phase 2 trial of patients with gonorrhea ,  
. 
The AUC and C max values for zoliflodacin at the various doses also point to a margin of safety, 
as seen by [CONTACT_707763] (no observable adverse effect level) values.8 
Potential for Drug -Drug Interactions  
Zoliflodacin is a  in preclinical studies. In vitro and in vivo 
metabolism across species indicate that the compound is  
. As a single dose therapy with no evidence of 
, the compound is not expected to show lasting 
effects. The potential for drug -drug interactions has been evaluated using a physiologically -based 
PK model developed with the  .8 In summary:  
1. Zoliflodacin as a victim : Single doses of zoliflodacin ranging from  
 
 
 
 
 
 
. The primary 

DMID Protocol 16 -0118 Version 2.0 
Zoliflodacin  25 January 2018  
 ________________________________ ________________________________ ________________________________ ______  
21 PK driver for efficacy of zolifl odacin is  
. 
2. Zoliflodacin as a perpetrator : Zoliflodacin is predicted to  
 
. The extent of the interaction is not predicted to differ 
between the zoliflodacin . This  
 
 administration of zoliflodacin . 
Safety 
In vitro studies : There was no  
 There was no  inhibition of  
  
Some fluoroquinolones induce QT prolongation leading to arrhythmia s and torsades de  pointes, 
which have been correlated with binding to the hERG K+ channel. I n contrast, zoliflodacin  
showed  
 
 
 
Animal pharmacology and toxicology studies : Zoliflodacin was well tolerated – as a  
 
. There was  
 
 
 
 
 
 
 
 
 At 
this highest dose tested,  
 
 These effects were  
 There were  
 
 

DMID Protocol [ADDRESS_961688] been assessed  
 Administration at   
 
 
 
. 
Human trials: Three trials have evaluated the safety of zoliflodacin in humans.8 
In healthy subjects in the Ph ase 1 trials,  
 
 
.8,12 
In patients in the Phase 2 trial, zoliflodacin was generally safe and well tolerated. AEs reported 
were generally mild, were non -serious, and none led to trial discontinuation.  The AE and 
laboratory safety profile s of zoliflodacin w ere generally similar to th ose of ceftriaxone.  The AE 
profile of zoliflodacin 2  g was generally similar to that of zoliflodacin 3  g; headache was more 
common in the zoliflodacin 3 -g group (9%) compared to the zoliflodacin 2 -g group (0%).  
Dysgeusia was not reported in the Phase 2 trial. Vomiting was reported by [CONTACT_707764] 3  g.8,13 
There were no AEs reported at a frequency of ≥5% when the AE profiles of the zoliflodacin 2-g 
and zoliflodacin 3-g groups were combined. The most common AEs reported with zoliflodacin 
(≥3% based on the zoliflodacin 2-g and zoliflodacin 3g groups combined and excluding 
infection-related AEs) were diarrhea, headache, and nausea. 8,[ADDRESS_961689] uncomplicated 
gonorrhea caused by N. gonorrhoeae  strains susceptible or resistant to currently available 
therapi[INVESTIGATOR_014]. These findings supported the ongoing clinical development of zoliflodacin as a 
potential new therapeutic option for uncomplicated gonorrhea. The recently completed Phase 2 
clinical trial suggests that zoliflodacin doses in the range of 2  g to 3 g are therapeutic. The 
present clinical trial will further characterize the PK characteristics and safety profile of a high 4 -
g dose of zoliflodacin and evaluate whether it can be used in a planned thorough QTc study . 
2.2.2 Rationale for Dose Selection  
Regulatory guidance ICH/FDA E14 has emphasized the need to obtain robust data on the effect 
of new chemical entities on ECG parameters , focusing on cardiac repolarization as measured by 
[CONTACT_707765].14 To obtain these data , the potential of a single therapeutic dose and a single 
supratherapeutic dose  of the study drug  to prolong cardiac repolarization is measured. The 4-g 
dose of a previous formulation of zoliflodacin  was found to be safe and well tolerated  in a Phase 
1 trial. The current trial will further characterize the PK and safety profiles of the 4-g dose of a 
new zoliflodacin formulation. This dose could result in drug exposures that are multiples of the 
proposed 2-g therapeutic dose  and meet the requirements for a sup ratherapeutic dose according 
to the ICH/FDA E14 Guidance for thorough QTc studies. [ADDRESS_961690] common  AEs reported with zoliflodacin in the Phase 1 
trials were dysgeusia and headache, and in the Phase 2 trial (≥3% based on the zoliflodacin 2 -g 
and zoliflodacin 3 -g groups combined and excluding infection -related AEs) were diarrhea, 
headache, and nausea. These events will continue to be monitored and evaluated . 
2.3.2 Potential Risks  
The potential risks to subjects participati ng in the trial are those related to PO dosing of 
zoliflodacin , and associated study procedures ( venipuncture , IV catheter insertio n, ECG patch 
application , and blood sampling). 
 
DMID Protocol [ADDRESS_961691] to   
 
 
 
 
 
 
. The effects of zolif lodacin  
 
 Based on these preclinical data and the 
gonorrheal clinical indication, in current and future clin ical trials:  
• Female subjects  will be pregnancy tested prior to administration of zoliflodacin and at the 
end of the trial  and will be required to use specified birth control methods for 30 days 
following final study visit.  

DMID Protocol 16 -0118 Version 2.0 
Zoliflodacin  25 January 2018  
 ________________________________ ________________________________ ________________________________ ______  
25 • Male subjects will be required t o use specified birth control methods for 90 days 
following final study visit and will be advised not to donate sperm during this period.   
Venipuncture and IV Catheter Placement  Risks 
Venipuncture : Venipuncture causes transient discomfort and may cause fainting. Bruising at the 
site of venipuncture may occur, but can be prevented or lessened by [CONTACT_694352]. Infection at the site is possible but highly unlikely as aseptic techniq ue will be used. 
IV catheter placement: An indwelling catheter may be placed in an arm vein (preferabl y 
antecubital) for frequent blood drawing for PK measurements. The catheter may cause phlebitis 
with signs of redness and warmth at or near the IV inserti on site, and thrombophlebitis with a 
hard area palpable near the IV insertion site. These risks are minimal as the IV catheters , when 
used, are only used briefly after dosing. Careful inspection of the catheter site, including 
visualization of blood return, and withdraw al of the catheter if needed  will minimize this risk. 
There is a risk of infection; however, this is a small risk as aseptic technique will be used. 
Additional Risks  
ECG: Possible side effects from ECG patches include a rash or minor ir ritation of the skin.  
Blood draws : The amount of blood drawn is about 18 mL during the Screening Visit and Day -1 
period, 74 mL during the inpatient period (Day s 1-4), and 92 mL during the entire trial 
(Appendix D ). Additionally, small amounts of blood loss may occur if an IV catheter is used or 
additional blood samples are c ollected (for repeat laboratory testing, evaluation of AE, etc.) . 
Overall, the amount of blood that may be drawn during the trial is within the a mount that 
considered safe to be drawn during short or extended periods, respectively, and not excessive for 
the safety and PK assessment requirements of Phase 1 trials. However, there is a small risk that 
some subjects may develop mild symptoms of hypovolemia or anemia during the trial. These are 
reversible with specific treatment (fluid replacement, good nutrition, vitamins , or iron 
supplementation).  
2.3.3 Known Potential Benefits  
The trial has no benefit for the subjec ts participating in the trial. Knowledge gained in th e trial 
could be of benefit to public health and to individuals with gonorrhea or at risk of acquiring  it. 
DMID Protocol 16 -0118 Version 2.0 
Zoliflodacin  25 January 2018  
 ________________________________ ________________________________ ________________________________ ______  
26 3 OBJECTIVES AND OUTCO ME MEASURES  
3.1 Study Objectives  
3.1.1 Primary 
• To evaluate the plasma PK of zoliflodacin after administration of a single 4 -g oral dose 
under fasting conditions  
3.1.2 Secondary  
• To evaluate the safety and tolerability of a single 4 -g oral dose of zoliflodacin  
3.2 Study Outcome Measures  
3.2.1 Primary  
• Cmax, Tmax, AUC (0-last), and other PK parameter s for zoliflodacin determined using plasma 
concentrations of zoliflodacin  in blood samples collected on Day 1  [baseline (30 min 
before dosing) and 0.5 h, 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, and 12 h  after dosing ], Day 2 [24 h 
and 36 h after dosing ], Day 3 [48 h after dosing ], and Day 4 [72 h after dosing ], or ET, 
and measured using a validated HPLC -MS/MS method 
3.2.2 Secondary  
• The occurrence of treatment -emergent SAE s from administration of zoliflodacin on Day 
1 to Final Visit (Day 8 ± 2), or ET 
• The occurrence of unsolicited treatment -emergent AEs from administration of 
zoliflodacin on Day 1 to Final Visit (Day 8 ± 2) , or ET 
• The changes from baseline (up to 60 min before dosing) in VS following administration 
of zoliflodacin , as measured on Day 1 [1 h, 2 h, and 4 h after dosing ], Days 2, 3 , and 4 
[24 h, 48 h, and 72 h , respectively,  after dosing ], and Final Visit (Day 8 ± 2) , or ET 
• The changes from baseline (Day  -1) in clinical laboratory values following administration 
of zoliflodacin , as measured on Day 4, or ET  
• The changes from baseline (up to 60 min before dosing) in ECG parameters following 
administration of zoliflodacin , as measured on Day 1 [1 h, 2 h, and 4 h after dosing ] and 
Day 4 [72 h after dosing ], or ET 
 
DMID Protocol [ADDRESS_961692] will receive a single 4g dose of zoliflodacin (2 x 
2 g sachets of zoliflodacin ) after at least an 8-h fast, which will continue for at least 4 h after 
dosing. Consumption of wat er will be permitted during the fasting period. Subjects will be 
monitored as inpatient s in the Clinical Trial Unit (CTU)  up to Day 4 and at  the Final Visit  (Day 8 
± 2). 
Subjects who consent to participate will be enrolled in the trial if they meet all  inclusion and 
none of the exclusion  eligibility criteria. Laboratory assessments at Screening Visit will include 
testing for serology  (HIV, HBsAg, and HCV), drugs of abuse , and alcohol. Serum pregnancy 
testing will be done in all women and serum FSH levels will be measured only in post-
menopausal women. Safety assessments at scheduled visits will include MH, VS, PE, 12-lead 
ECG, and clinical laboratory tests including CBC with differential, comprehensive metabolic 
(chemistry) panel, and UA. Treatment -emergent AEs  and SAEs  will be assessed from the time of 
dosing to the end of the trial. Plasma for PK analysis  will be collected at scheduled time points 
before and after initiati on of dosing on Day [ADDRESS_961693] of the trial. A scheduled SMC meeting will 
be held after all subjects complete the trial to review safety data , and advise on using the 4 -g 
dose in a subsequent thorough QTc study. If criteria for halting the trial (as listed in Section 
9.5.1) are met during dosing on Day 1, an ad hoc SMC meeting will be held to review all 
available safety data and to make recommendations about the dosing of all further sub jects in the 
trial. An independent safety monitor ( ISM), who is local to the CTU, will review SAEs and other 
severe safety signals and provide an independent analysis to the Site PI, SMC, and DMID. 
4.1 Sub-studies 
No sub-studies are planned.  
DMID Protocol 16 -0118 Version 2.0 
Zoliflodacin  25 January 2018  
 ________________________________ ________________________________ ________________________________ ______  
28 5 STUDY ENROLLMENT AND WITHD RAWAL  
Only subjects who meet all inclusion criteria and none of the exclusion criteria will be eligible 
for enrollment into th e trial. No exemptions are granted on Inclusion/Exclusion Criteria in DMID 
sponsored trials. 
Eight healthy mal e and female subjects , aged [ADDRESS_961694] to be eligible for study participation : 
1) Informed consent form (ICF) understood and signed before initiating any study 
procedures  
2) Healthy male or female, as assessed by [CONTACT_707766] (listed on FDA Form 
1572)  
3) Willingness to comply with and be available for all protocol procedures including 
inpatient confinement for about 4 days  and availability for follow -up for the duration of 
the trial 
4) Aged 18 to 45 years inclusive on the day of study drug dosing 
5) Body Mass Index (BMI) ≥18.5 and ≤30 kg/m2 and weight ≥50 kg (110 lbs.) and 
≤100 kg (220 lbs.) 
6) In female subject s of childbearing potential, a negative serum pregnancy test at Screening 
Visit and on Day -1 
• Note: A woman is considered of childbearing potential unless post -menopausal (≥ 1 
year without men ses without other known or suspected cause and with a FSH level in 
the menopausal range) , or surgically sterilized (hysterectomy, salpi[INVESTIGATOR_1656], 
oophorectomy or tubal ligation/occlusion ) 
7) If female, not pregnant, not breast feeding, and not planning on becoming pregnant 
during the trial and for 30 days after study participation  
8) Females of childbearing potential and males agree to use acceptable contraception for the 
duration of the trial and for 30 days  (females) or 90 days (males)  after final study visit 
• Note: A highly effective method of birth control is defined as one with a low failure 
rate (i.e., less than 1 percent per year) according to the CDC criteria.15 These include 
progestin implants, intrauterine devices (I UDs), surgical (hysterectomy , 
salpi[INVESTIGATOR_1656], oophorectomy  or tubal ligatio n/occlusion ; vasectomy) , or abstinence. 
DMID Protocol 16 -0118 Version 2.0 
Zoliflodacin  25 January 2018  
 ________________________________ ________________________________ ________________________________ ______  
29 Use of methods with higher failure rate (such as progestin injectables, combined oral 
hormonal contraceptives, condoms, and diaphragms) will n ot be acceptable when 
used alone, but they could be considered if used in combination with another method 
(e.g., a female using combined oral contraceptives if her male partner is sterile, or if 
she and her non -sterile male partner use a double -barrier met hod), after consultation 
with the DMID Medical Officer. 
9) Male subjects must agree to refrain from sperm donation for the duration of the trial and 
for 90 days after Final Visit 
10) Laboratory tests, as outlined in Section [IP_ADDRESS], are in the normal reference range with 
acceptable exceptions as noted in Section [IP_ADDRESS] and Appendix B   
11) VS, as outlined in Section 8.1.6, are within the acceptable range per Appendix B  
12) Has adequate venous access for blood collection  
13) Urine drug screen is negative for tested substances  (see Section [IP_ADDRESS]) 
14) Alcohol test (breathalyzer) is negative  
15) Willing to abstain from alcohol consumption for [ADDRESS_961695] to be eligible for study participation : 
1) History of a chronic medical or surgical condition that wou ld interfere with the accurate 
assessment of the trial’s objectives or increase the subject’s risk profile  
• Note: Chronic medical conditions include: diabetes mellitus; asthma requiring use of 
medication in the year before screening; autoimmune disorder suc h as lupus 
erythematosus, Wegener’s, rheumatoid arthritis, thyroid disease; cardiovascular 
disease, including  coronary artery disease or cerebrovascular disease, or surgery; 
syncope related to cardiac arrhythmia or unexplained; chronic hypertension; 
malignancy except low -grade (squamous and basal cell) skin cancer thought t o be 
cured; chronic renal, hepatic, pulmonary, or endocrine disease, myopathy, or 
neuropathy; gastrointest inal or biliary surgery.  
2) History of hypersensitivity or severe allergic reaction of any typ e to medications, bee 
stings, food, or environmenta l factors 
• Note: Severe allergic reaction is defined as any of the following: anaphylaxis, 
urticaria, or angioedema  
 
3)  Active allergic symptoms to seasonal and animal allergens that require treatment   
DMID Protocol 16 -0118 Version 2.0 
Zoliflodacin  25 January 2018  
 ________________________________ ________________________________ ________________________________ ______  
30 4) A marked baseline prolongation of ECG intervals , or HR <45 bpm or >100 bpm on ECG 
measurements  
• Note: The following are considered prolonged ECG intervals: QTc/QTcF > 449 msec 
in males and females; PR  >209 msec; and QRS  >110 msec  
5) Clinically significant abnormal ECG  results 
Note: Clinically significant abnormal ECG results include: complete left or right 
bundle branch block; other ventricular conduction block; 2nd degree or 3rd degree 
atrioventricular (AV) block; sustained atrial or ventricular arrhythmia; two premature 
ventricular contractions in a row; pattern of ST elevation felt consistent with cardiac 
ischemia; evidence of a previous myocardial infarction (MI), left ventricular 
hypertrophy (LVH), or more than minor non -specific ST -T wave changes; or any 
condition deemed clini cally significant by a study investigator . 
6) Abnormal renal function  
Note: Normal renal function is defined as normal creatinine [per criteria in Appendix B ] 
and normal estimated glomerular filtration rate (eGFR)  [i.e., >80.0 mL/min] values 
according to Cockroft -Gault. 
7) Positive serology results for HIV, HBsAg, or HCV  
8) Febrile illness with temperature >37.6°C for <7 days before dosing 
9) Donated whole blood or bloo d products within 60 days before dosing, or plans to donate 
before Final Visit (Day 8 ± 2)  
•  Note: Blood products include RBC s, WBCs, platelets, and plasma 
10) Known allergic reactions to any of the study drug components present in the formulation 
or in its processing, as listed in the IB 
11) Treatment with another investigational product within [ADDRESS_961696] of the study drug (whichever is longer)  
• Note: Investigational products include a drug, vaccine, biologic, device or blood 
product 
12) Active drug or alcohol use , abuse, or dependence within 12 months before Screening 
Visit that, in the opi[INVESTIGATOR_871], would interfere with adherence to study 
requirements  
13) Use of any prescription medication within 30 days before dosing or planned use during 
the study period  except as noted below and approved by [CONTACT_469406]  
• Note 1: Prohibited medications include moderate or strong CYP3A4 inducers  (per 
Section 6.9) ; antibiotics; injectable or oral antidiabetic drugs; anti -lipid drugs; 
DMID Protocol 16 -0118 Version 2.0 
Zoliflodacin  25 January 2018  
 ________________________________ ________________________________ ________________________________ ______  
31 immunosuppressive  agents; immune modulators; oral corticosteroids; anti -neoplastic 
agents; any vaccine (licensed or investigational) except licensed influenza vaccine 
during the flu seas on, which is allowed  7 days before or after dosing . 
• Note 2: Allowed medications include : oral contraceptives;  H1 antihistamines; 
topi[INVESTIGATOR_2855]/ intranasal corticosteroids; nonsteroidal anti -inflammatory drugs [NSAIDS]; 
licensed influenza vaccine during the flu s eason, 7 days before or after dosing . 
14) Use of any non -prescription medication, herbal prepara tion, or nutritional supplement 
within 15 days before dosing or planned use during the study unless approved by [CONTACT_306972]  
• Note: Exception s: St. John’s wart is not allowed within 30 days of dosing, vitamins 
and OTC medications taken for a brief period ( <48 h) for the treatment of common 
symptoms (such as headache, indigestion, muscle pain) may be allowed as approved 
by [CONTACT_707767]. 
 
15) Intake of caffeinated beverages or food within 72 h before dosing or a history of high 
caffeine consumption  (e.g., in the last 4 months drinking >5 cups of coffee/day ) 
16) Smoking or use of tobacco or nicotine -containing products within 15 days before dosing 
17) Engagement in strenuous exercise within 15 days before dosing (e.g., marathon runn ing, 
long distance cycli ng, weight lift ing) and during the study period  
18) Any specific behavioral or clinical condition that in the judgment of the investigator 
precludes participation because it could affect compliance with study procedures or 
subject safety  
19) Plans to enroll or is already enrolled in  another clinical trial that could interfere with 
safety assessment of the study drug  at any time during the study period  
• Note: Includes trials that have a study intervention such as a drug, biologic, or 
device. 
20) Is a study site employee or staff member who is paid entirely or partially by [CONTACT_707768]/NIAID contract for the DMID -funded trial 
• Note: Site employees or staff include the PIs , sub-investigators , or staff who are 
supervised by [CONTACT_978] [INVESTIGATOR_11637]-investigators . 
DMID Protocol 16 -0118 Version 2.0 
Zoliflodacin  25 January 2018  
 ________________________________ ________________________________ ________________________________ ______  
32 5.3 Treatment Assignment Procedures  
5.3.1 Enrollment Procedures  
This is a Phase 1 , open-label clinical trial of a single dose of zoliflodacin . Eight healthy subjects 
who consent to participate in the trial and meet the eligibility criteria will be enrolled following 
admittance to the CTU and confirmation of eligibility. Subjects will be registered using a web -
based application developed by [CONTACT_140171], the Data Coordinating C enter (DCC) 
for the trial. 
Per ICH guideline E6: GCP, screening records will be kept at the participating  site to document 
the reason why an individual was screened but did not meet trial entry criteria , by [CONTACT_707769] (Electronic Data Capture System).  
Subjects will be enrolled online using the enrollment module of AdvantageEDCSM after the 
demographic and eligibility data have been entered into the system.  
Instructions for us ing the enrollment module are included in the AdvantageEDCSM User’s Guide.  
5.3.[ADDRESS_961697] will be discontinued from participation in the trial if any of the following reasons 
occur before dosing: 
• Request by [CONTACT_92237] ; 
• Failure to receive the study drug due to difficulty ingesting it. 
 
A subject may be removed from the trial after dosing for the following reasons; however, 
whenever possible the subject should be followed for safety per protocol:  
• Failure to adhere to protocol requirements;  
• Loss to follow-up; 
• Request of primary care provider;  
• Request of the Institutional Review Board (IRB)/Ethics Committee  (EC), Food and 
Drug Administration (FDA), or DMID; 
DMID Protocol 16 -0118 Version 2.0 
Zoliflodacin  25 January 2018  
 ________________________________ ________________________________ ________________________________ ______  
33 • The subject’s well -being, based on the opi[INVESTIGATOR_871];  
• The occurrence of a n SAE or AE warranting withdrawal ; 
• Failure to ingest the entire volume of drug suspension ; 
• Vomiting within [ADDRESS_961698] the content of the second  study drug suspension will not be withdrawn from 
the study or replaced. Subjects who received any amount of the study drug but withdraw from 
the trial will be encouraged to continue follow -up (with subjects’ consent) for safety  assessments 
and PK sample collection . Subjects withdrawing will be asked to complete a final termination 
visit if they do not wish to be followed per protocol.  
5.3.[ADDRESS_961699] to Follow -up 
In the case of subjects who fail to appear for a follow -up assessment, extensive effort (i.e., three 
documented contact [CONTACT_92238], e -mail, etc., made on separate occasions and 
followed by a certified letter) will be made to locate or recall them, or at least to determine their 
health status. These efforts will be documented in the subjects’ records.  
5.3.6 Termination of Study 
Although the sponsor (DMID) has every intention of completing the trial, it reserves the right to 
terminate the trial at any time for clinical or administrative reasons. In addition, the trial may be 
terminated or suspended at the request of the FDA , SMC, or IRB/EC. 

DMID Protocol 16 -0118 Version 2.0 
Zoliflodacin  25 January 2018  
 ________________________________ ________________________________ ________________________________ ______  
34 6 STUDY INTERVENT ION/INVESTIGATIONAL P RODUCT  
6.[ADDRESS_961700] Description  
The chemical name [CONTACT_707793]  (also known as ETX0914 and AZD0914)  is (2R,4S,4aS) -11-
fluoro-2,4-dimethyl-8-[(4S)-4-methyl-2-oxo-1,3-oxazolidin -3-yl]-1,2,4,4a-tetrahydro -2'H,6H-
spi[INVESTIGATOR_2152][1,4-oxazino[4,3 -a][1,2]oxazolo[4,5 -g]quinoline -5,5'-pyrimidine] -2',4',6'(1'H,3'H) -trione.  
Zoliflodacin is a spi[INVESTIGATOR_694319], with a novel mode of action. It is a 
first-in-class oral gyrase inhibitor being developed for treatment of uncomplicated gonococcal 
infection, including cases caused by [CONTACT_707770] a vailable treatments . 
6.1.[ADDRESS_961701] by [CONTACT_122830], the study 
drug will be shipped to the following address:    
DMID-Clinical Materials Services (CMS)  
Fisher BioServices  
[ADDRESS_961702] 
Germantown, MD [ZIP_CODE]  
Tel: [PHONE_6136] 
Fax: [PHONE_6137] 
E-mail: [EMAIL_1395]   
The study drug will be shipped from DMID -CMS to the CTU upon request and approval by 
[CONTACT_122830]. Details will be provided in the protocol -specific Manual of Procedures (MOP).  
6.1.2 Formulation, Packaging, and Labeling  
Zoliflodacin is presented as granules for oral suspension, 50 % wt/wt , packaged in a  single 
sachet. Each sachet contains 2 g spray -dried Zoliflodacin, co -formulated with  
 
. 
Each sachet will be labeled in compliance with applicable regulatory requirements, including the 
FDA-required cautionary statement “Caution - New drug -Limited by [CONTACT_4496] (or [LOCATION_002]) 
Law to Investigational Use Only.”    
6.1.[ADDRESS_961703] Storage and Stability  
The zoliflodacin granules for oral suspension , 50% (w/w) should be stored at 2 -8°C in the 
primary packaging.   

DMID Protocol [ADDRESS_961704] be monitored by [CONTACT_707771]. Documentation of temperature monitoring shou ld be maintained. Further 
details are described in the MOP.  
6.2 Dosage, Preparation , and Administration  of Study Intervention/  
Investigational Product  
All subjects will receive a single  4-g PO dose (2 sachets of 2 g)  of zoliflodacin  in the morning of 
Day 1 in a staggered fashion several minutes apart . 
The study drug will be inspected for damage, contamination, discoloration , or particulate matter  
before use. Any study drug  that fails inspection should be quarantined at 2 -8°C (35.6 -46.4°F) 
and labeled ‘Do Not  Use’ until further notice. The Site PI [INVESTIGATOR_707747] 
[EMAIL_5255] and DMID Clinical Project Manager (CPM) for 
further instructions before administering any additio nal study drug . Based on the information 
collected, DMID and/or Entasis will determine whether the affected study drug can be used. If it 
cannot be used, the site will receive specific instructions on how to return it to DMID CMS or 
destroy it on site . 
A detailed procedure will be described in  the MOP.   
Eligible subjects who provide informed consent, undergo screening pro cedures, and qualify , 
meeting all inclusion and none of the exclusion criteria  for the trial, will receive a single 4-g dose 
(2 sachets of 2 g  of zoliflodacin  reconstituted on the same day and administered in  a total of  
) orally after an overnight fast . The dose will be administered in a standardized 
cup as described in the MOP. After the  of zoliflodacin is administered, an additional   
will be added to the same cup and consumed b y the subject to chase the initial 
dose. Dosing should be completed within [ADDRESS_961705] for an additional 4 h  while water is  allowed ad lib. 
Refer to the protocol -specific MOP for detailed information on the preparation and administration 
of zoliflodacin . 
6.3 Modification of Study Intervention/Investigational Product for a 
Subject 
Not applicable for a single cohort study. See Study Halting Criteria , Section 9.5.1 

DMID Protocol 16 -0118 Version 2.0 
Zoliflodacin  25 January 2018  
 ________________________________ ________________________________ ________________________________ ______  
36 6.3.1  Overdose  
An overdose is defined as a dose greater than the high -dose level evaluated in the trial. All 
overdoses should be reporte d; if the overdose is associated with an AE, then the AE should also 
be reported. In the event of an overdose of zoliflodacin, the investigator should use clinical 
judgment in treating the overdose and contact [CONTACT_434382] (MM). The 
investigato r should refer to the relevant document(s) for detailed information regarding 
warnings, precautions, contraindications, AEs, and other significant data pertaining to 
zoliflodacin. Such documentation may include but not be limited to the IB.  
6.4 Accountability Procedures for the Study Intervention/Investigational 
Product(s)  
The Site PI [INVESTIGATOR_707748], and has ultimate 
responsibility for accountability. The Site PI [INVESTIGATOR_707749]. If 
delegated, the Site RP will be responsible for maintaining complete records and documentation 
of the study drug’s receipt, accountability, disp ensation, temperature monitoring,  storage 
conditions, and final disposition.  
All study drugs, whether administered or not, must be documented on the appropriate study drug 
accountability record or dispensing log. Used and unused zoliflodacin sachets will be retained 
until monitored and released for disposition per DMID requirements.  
Upon completion of the trial and after the final monitoring visit, any remaining unused study 
drug will either be returned or destroyed appropriately at the clinical site as pe r sponsor 
requirements and instructions, or in accordance with disposition plans.  
6.[ADDRESS_961706] Compliance with Study Intervention/  
Investigational Product/Device   
Since each dose of zoliflodacin will be administered by [CONTACT_8786], subject compliance is not 
anticipated to be an issue. Complete information regarding any partial or interrupted dosing will 
be documented.  Subjects unable to ingest the full amount of the initial  of study drug 
suspension or who vomit within 24 h after dosing  will be withdrawn from the study and replaced 
(See Section 5.3.3 and 5.3.4). Subjects who do not ingest the content of the second  study 
drug suspension will not be withdrawn  from the study . 
6.6 Prior and  Concomitant Medications/Treatments  
Medications include the following : prescription drugs , birth control hormonal preparations, non -
prescription medication , herbs, vitamins, nutritional supplements, and illicit and recreational 

DMID Protocol 16 -0118 Version 2.0 
Zoliflodacin  25 January 2018  
 ________________________________ ________________________________ ________________________________ ______  
37 substance s. Medications taken before or after dosing will be reported as Prior Medications or 
Concomitant Medications  (ConMeds) , respectively . 
Prior prescription medication information will be recorded at Screening Visit and, except  for 
hormonal contraceptives, should not be taken for 30 days before dosing or during the study 
period.  
Zoliflodacin should not be co -administered in subjects using strong (i.e. avasimibe, 
carbamazepi[INVESTIGATOR_050], phenytoin, rifampin, and St. John's wort) or moderate (i.e. efavirenz, bosentan, 
etravirine, modafinil, and nafcillin) inducers of CYP3A4.  These drugs should not be taken for 30 
days before dosing  and during the study period . 
A vaccine should not be received within 30 days before dosing or before the end of the trial, 
except for licensed influenza vaccine during the flu season, which may be administered up to 7 
days before or after dosing.  
Non-prescription medications, herb s, vitamins, and nutritional supplements should not be  taken 
within 15 days before dosing. OTC medications taken for a brief period (<48 h) for the treatment 
of common symptoms (such as headache, indigestion, muscle pain) may be allowed as approved 
by [CONTACT_469406].  
Allowed medications include: oral contraceptives; H1 antihistamines; topi[INVESTIGATOR_2855]/ i ntranasal 
corticosteroids; nonsteroidal anti -inflammatory drugs (NSAIDS); licensed influenza vaccine 
during the flu season, 7 days before or after dosing.   
Blood/blood products ( RBCs, WBCs, platelets, and plasma) should not be donated within 60 
days of dos ing or received before Final Visit.  
Following dosing , each new concomitant medication and changes to existing medications will be 
recorded. Subjects will be required not to utilize non -study medication during the trial except 
those deemed necessary by [CONTACT_7910] [INVESTIGATOR_11637] -investigator.  
Any drug (e.g.,  non-prescription medications , herbal supplement s, vitamins , or prescription  
medications ) or vaccine or blood/blood products used by [CONTACT_469407]’s source documents  and on the appropriate  electronic case report form 
(eCRF), and the PI [INVESTIGATOR_469356] (listed on FDA Form 1572) will note whether 
the use was medically indicated and immediately necessary . Any use of medications not 
authorized by [CONTACT_1758] P I or authorized clinician will be recorded as a deviation.  
 
6.[ADDRESS_961707] database and IRB -approved advertisements and social media. IRB-approved, 
prescreen questionnaires will be used to determine if subjects meet study requirements before 
scheduling screening visits . 
7.2 Screening Visit (Day -21 to Day -2) 
The following will be done within 21 days before study drug dosing:  
• Obtain informed consent  
• Assign a study ID number to subjects who consent to participate  
• Review inclusion/exclusion criteria to ensure the subject is eligible for enrollment  
• Record demographics including age, gender, race, and  ethnicity 
• Obtain contact [CONTACT_3031]  
• Obtain MH    
• Review history of prior medications, including all taken within 30 days  
• Perform complete PE (except genital, rectal, and breast exams) by [CONTACT_707772] 1572  
• Obtain height and weight,  and calculate BMI (wt [kg] / ht [m2]) 
• Take VS (supi[INVESTIGATOR_694327], HR, respi[INVESTIGATOR_697], and oral temperature)  
• Obtain blood and urine samples for clinical laboratory tests  
• Obtain blood samples for viral serology  
• Obtain serum for β -HCG pregnancy test from all women  
• Obtain serum for FSH level from only post -menopausal women  
• Obtain urine sample for toxicology  
• Perform breathalyzer test for alcohol use  
• Obtain a 12 -lead ECG wi th 10-sec rhythm strip  
• Counsel on the avoidance of pregnancy for women of childbearing potential  
• Counsel both male and females on the use of contraception  
• Counsel on the avoidance of alcohol, marijuana, illicit drugs, and prohibited medications  
Subjects wh o meet the eligibility criteria will be contact[CONTACT_707773] -[ADDRESS_961708] 
positive for HIV, HBsAg, and/or HCV infection, they will be inform ed that test results may be 
reported to the local Health Authorities according to State or Local Law.  
7.3 Enrollment/Baseline  
7.3.1 Admission Visit (Day -1, Unit Check -in) 
Subjects meeting all of the inclusion and none of the exclusion  criteria at Screening Visit will 
check into the CTU on Day -1 and the following procedures will be performed:  
• Review inclusion/exclusion criteria to ensure the subject remains eligible for enrollment  
• Update MH  
• Update Prior Medications  
• Perform abbreviated PE (A n abbreviated  complete PE will be performed if the Screening 
PE was completed >7 days from dosing)  
• Obtain VS  
• Obtain weight  
• Obtain blood and urine samples for clinical laboratory tests (if screening samples were 
collected >7days from dosing)  
• For all women, a serum β-HCG pregnancy test will be done, and negative results 
confirmed before dosing  
• Obtain urine sample for toxicology  
• Perform breathalyzer test for alcohol use  
• Obtain [ADDRESS_961709] access to water during that period . 
7.4 Inpatient period (Days 1 to 4)  
7.4.1 Administration of Study Drug (Day 1)  
A subject will be enrolled in the tri al and receive the study drug on Day 1 if he/she continues 
meeting the eligibility criteria by [CONTACT_707774] 16 -0118 Version 2.0 
Zoliflodacin  25 January 2018  
 ________________________________ ________________________________ ________________________________ ______  
41 Before Dosing:   
• Withhold breakfast but allow access to water   
• Update MH  
• Update Prior Medication s 
• Obtain VS ( within 60 min before dosing)  
• Perform symptom -directed PE (if applicable)  
• Obtain 12 -lead ECG with 10 -sec rhythm strip (within 60 min before dosing)  
• May insert IV catheter for blood collection into a forearm vein  
• Obtain blood (plasma) PK sample (30 min before dosing)  
Dosing:  
• Administer a single 4 -g dose of zoliflodacin orally as a  followed by  
[CONTACT_707775] 
• Withhold food until 4 h after dosing but allow access to water  
After Dosing : 
• Obtain VS at 1 h (±10 min), 2 h (±10 min), and 4 h (±10 min) af ter dosing;  more frequent 
monitoring will be at the PI’s discretion based on subject’s clinical presentation  
• Perform symptom -directed PE (if applicable)  
• Perform AE and SAE assessments  
• Obtain 12 -lead ECG with 10 -sec rhythm strip at 1 h (±10 min), 2 h (±10 min), and 4 h 
(±10 min) after dosing  
• Obtain blood (plasma) PK samples at 0.5 h (±5 min), 1 h (±5 min), 2 h (±5 min), 3 h (±10 
min), 4 h (±10 min), 6 h (±10 min), 8 h (±15 min), and 12 h (±15 min) after dosing  
• Document ConMeds  
7.4.2 In-patient Follow -up Day 2  
• Update MH  
• Obtain VS  
• Perform symptom -directed PE (if applicable)  
• Perform AE and SAE assessments  
• Obtain blood (plasma) PK samples at 24 h (±2 h) and 36 h (±2 h) after dosi ng 
• Document ConMeds  
7.4.3 In-patient Follow -up Day 3  
• Update MH  
• Obtain VS  
• Perform symptom -directed PE (if applicable)  

DMID Protocol 16 -0118 Version 2.0 
Zoliflodacin  25 January 2018  
 ________________________________ ________________________________ ________________________________ ______  
42 • Perform AE and SAE assessments  
• Obtain blood (plasma) PK samples at 48 h (±2 h) after dosing  
• Document ConMeds  
7.4.4 Discharge from Unit (Day 4)  
The subject is eligible for discharge from the CTU at 72 h (±2 h) after dosing, after the following 
assessments have been performed, and if no clinically important abnormalities are confirmed by 
[CONTACT_9154] [INVESTIGATOR_707750]:  
• Update MH  
• Obtain VS  
• Perform abbreviated PE  
• Perform AE and SAE assessments  
• Document ConMeds  
• Obtain 12 -lead ECG with 10 -sec rhythm strip at 72 h (±2 h) after dosing  
• Obtain blood (plasma) PK samples at 72 h (±2 h) after dosing  
• Obtain blood and urine for clinical laboratory tests  
• Counsel women of childbearing potential on the avoidance of pregnancy  
• Counsel male and female subjects on the avoidance of pregnancy  
• Remind subjects to abstain from prohibited medications, alcohol, marijuana and illegal 
drugs 
• Instruct on the next scheduled visit  
• Discharge subject from the CTU after review of clinical laboratory tests, ECG, and other 
assessments by [CONTACT_976] [INVESTIGATOR_707751] 
7.5 Final Study Visit  (Day 8 ± 2)  
• Update MH  
• Obtain VS  
• Perform complete PE  
• Obtain weight  
• Collect blood for serum β -HCG pregnancy test in all females  
• Perform AE and SAE assessments  
• Update ConMeds  
• Counsel male and female subjects on the avoidance of pregnancy  
• Counsel female subjects to use appropriate contraception for 30 days after the final visit.  
• Counsel male subjects to use appropriate contraception and refrain from sperm donation 
for 90 days after the final visit.  
DMID Protocol 16 -0118 Version 2.0 
Zoliflodacin  25 January 2018  
 ________________________________ ________________________________ ________________________________ ______  
43 • Discharge from trial  after revie w of clinical laboratory tests, ECG, and other assessments 
by [CONTACT_976] [INVESTIGATOR_694329]  
7.6 Early Termination Visit  (if needed)  
• Update MH  
• Obtain VS  
• Perform complete PE  
• Perform AE and SAE assessments  
• Update ConMeds  
• Obtain 12 -lead ECG with 10 -sec rhythm strip  
• Obtain blood and urine for clinical laboratory tests  
• Collect blood for serum HCG pregnancy test in all females  
• Obtain blood PK sample  
• Counsel male and female subjects on the avoidance of pregnancy  
• Counsel female subjects to use appropriate contraception for 30 days after the ET visit.  
• Counsel male subjects to use appropriate contraception and refrain from sperm donation 
for 90 days after the ET visit. 
7.7 Unscheduled Visit  (if needed)  
A subject may return to the clinic for an unscheduled visit at any time. The following activities at 
a minimum should be performed:  
• Update MH  
• Obtain VS  
• Perform symptom -directed PE (if applicable)  
• Update ConMeds  
• Perform AE and SAE assessments  
• Obtain blood and/or urine for clinical laboratory tests (if applicable)  
• Counsel male and female subjects on the avoidance of pregnancy  
 
DMID Protocol 16 -0118 Version 2.0 
Zoliflodacin  25 January 2018  
 ________________________________ ________________________________ ________________________________ ______  
44 8 STUDY PROCEDURES /EVALUATIONS  
8.1 Clinical Procedures/Evaluations  
8.1.[ADDRESS_961710] be approved by [CONTACT_3488] /EC and executed before performing any study -
related activities.  
Informed consent will be obtained for all subjects participating in the trial before performing any 
screening assessments . Subjects may withdraw consent at any time. Participation in the trial may 
be terminated at any time without the subject’s consent as determined by [CONTACT_093].  
8.1.2 Demographics  
Demographic information (date of birth, gender, ethnicity, and race) will be recorded on the 
subject’s source documents and eCRF at Screening Visit. Name, address, phone number, and 
emergency contact [CONTACT_469412].  
8.1.3 Inclusion/Exclusion Criteria  
Eligibility screening of healthy subjects will be completed within [ADDRESS_961711]’s source documents and on the eCRF. 
Confirmation of eligibility will be performed before dosing on Day 1. 
Screening fa ilures and the reason for failure to meet the study eligibility requirements will be 
documented in the source documents and entered into the study database.  
8.1.[ADDRESS_961712]’s source document and eCRF. The MH will capture the subject’s 
current disease processes, past disease processes, history of hospi[INVESTIGATOR_059], history of surgery, 
allergies, and prior medications (taken 30 days before dosing) . Subjects will be queried regarding 
a history of significant medical disorders of the head, eyes, ears, nose, throat (HEENT), mouth, 
skin, and the cardiovascular , gastrointestinal , renal, urologic al, nervous, hematological, 
lymphatic, endocrine, musculoskeletal , and genital/reproductive systems. A history of cancer, 
autoimmune disease, immunodeficiency, psychiatric illness, and substance abuse will be 
specifically solicited. The MH will be obtained at Screening Visit and updated upon admittan ce 
to the CTU and before dosing on Day 1. After the study treatment, an interim MH will be 
obtained on all study days by [CONTACT_707776], 
noting any  changes since the previous study day or contact. Any worsening  of pre-dosing MH or 
new symptoms will be evaluated and reported as AEs.  
DMID Protocol 16 -0118 Version 2.0 
Zoliflodacin  25 January 2018  
 ________________________________ ________________________________ ________________________________ ______  
45 8.1.5 Physical Examination  
A complete PE  – except genital, breast, and rectal exams – will be performed at Screening Visit  
and Final Visit ( Day 8 ± 2) , or ET, and will assess general appea rance, HEENT, heart, lungs, 
abdomen, skin, musculoskeletal system, and lymph nodes, and include an abbreviated 
neurological exam.  
An abbreviated PE  will be performed on Day -1 and Day 4. If a complete PE was performed ≤7 
days before dosing, th en an abbreviated PE will not be performed on Day  -1. An abbreviated PE 
differs from a complete PE in that the abdomen  and neurological system  are not evaluated .  
A symptom-directed PE  will be performed before dosing on Day 1 and aft er dosing on Days 1, 2 , 
and 3, to evaluate new symptoms or treatment -emergent AEs, respectively.  
Height and weight will be measured , and BMI calculated , at Screening  Visit; only weight will be 
measured on Day -1 and at Final Visit  (Day 8 ± 2) . 
Refer to the protocol -specific MOP for fu rther details. The findings of each examination will be 
recorded on the subject’s source documents and eCRF. Any new findings on examination or 
worsening of existing conditions after dosing are to be reported as AEs.  
8.1.6 Vital Signs 
VS including resting (measured after supi[INVESTIGATOR_1919] 10 min ) systolic and diastolic BP, HR, 
respi[INVESTIGATOR_697], and oral temperature will be measured at Screening  Visit, on Day -1, before and 
after dosing on Day 1, on Days 2, 3 , and 4, and at Final  Visit, or ET. On Day 1, VS will be 
measured approximately 1 h before dosing , and 1 h (±10 min), 2 h (±10 min), and 4  h (±10 min) 
after dosing. On Days 2, 3 , and 4, VS will be measured  at 24 h (±2 h), 48 h (±2 h), and 72 h (±2 
h), respectively. Acceptable ranges are shown in Appendix B . 
VS that are considered  aberrant due to an error in measurement may be repeated. During 
screening and after dosing, an abnormal  VS measurement may be repeated twice more at rest, 
within [ADDRESS_961713] will be excluded (if at Screening  Visit) or 
the event re ported as an AE (if after dosing). If the second measurement is normal, a third 
measurement will be taken  at least after [ADDRESS_961714] is eligible (if at Screening  Visit) or there is no AE (if after dosing); if it is abnormal, the 
subject will be excluded (if at Screening  Visit) or an AE will be reported at the highest assessed 
grade (between first and third measurements) and graded for severity per Appendix C  (if after 
dosing). 
DMID Protocol 16 -0118 Version 2.0 
Zoliflodacin  25 January 2018  
 ________________________________ ________________________________ ________________________________ ______  
46 8.1.7 Electrocardiogram  
A 12-lead ECG and 10-sec rhythm strip will be obtained at Screening  Visit and on Days -1, 1, 
and 4, or ET. On  Day 1, a 12-lead ECG and 10-sec rhythm strip will be recorded within 1 h 
before dosing  and 1 h (±10 min), 2 h (±10 min), and 4 h (±10 min) after dosing . The ECGs will 
be reviewed by [CONTACT_978] [INVESTIGATOR_1660] a designated clinician (listed in FDA Form 1572) . ECGs will be 
performed after the subject rests quietly in a supi[INVESTIGATOR_21683] 5 min. To be eligible for 
participation, the QT/QTcF interval must be normal, and there must be no clinically significant 
ECG abnormalities. I f a question regarding ECG interpretation  arises, the study investigators will 
have the ECG reviewed by a cardiologist.  
8.2 Laboratory Evaluations  
Venipuncture sch edule and blood volumes are shown in Appendix A  and Appendix D . The 
blood volume for hematology and chemistry tests will be approximately 9 mL per sample 
(Appendix D ). 
8.2.1 Clinical Laboratory Evaluations  
[IP_ADDRESS] Screening and Safety Clinical Laboratory (Hematology, Chemistry , and 
Urinalysis) Tests  
Blood and urine samples for clinical laboratory tests will be collected at Screening  Visit, and on 
Days -1 (if not collected ≤7 days of dosing)  and 4, or ET. These tests will include:  
• Hematology (HEM): hemoglobin (Hgb), hematocrit (H ct), red blood cell (RBC)  count, 
platelet count, and white blood cell (WBC) count with absolute differential count  
• Chemistry (CHEM): serum creatinine,  with estimation of GFR,  blood urea nitrogen 
(BUN), glucose (fasting at least 4 h), total bilirubin, direc t bilirubin, alanine 
aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (AP), 
total protein, albumin, sodium, chloride, potassium, bicarbonate  (CO2), magnesium  
• Urinalysis (UA): Routine dipstick testing of clean -catch urine for blood, protein, and 
glucose; other coincidental tests will be recorded   
 Clinical laboratory tests at Screening Visit and Day -1 should be in the normal reference range 
with acceptable exc eptions, as shown below and in Appendix B : 
Elevated bilirubin due to documented Gilbert’s syndrome that is Grade 1 is allowable , but Grade 
2 or higher is exclusionary. (To document a subject has Gilbert syndrome, a diagnosis from the 
medical record must be provided or the PI [INVESTIGATOR_114307] a ‘presumptive ’ diagnosis of Gilbert 
syndrome in subjects with unconjugated hyperbilirubinemia on repeated testing (at least 2 
samples separated in time) who have otherwise normal serum ALT/AST and AP concentrations, 
and a normal CBC.)  
DMID Protocol 16 -0118 Version 2.0 
Zoliflodacin  25 January 2018  
 ________________________________ ________________________________ ________________________________ ______  
47 Elevated serum glucose, sodium, potassium, bicarbonate  (CO2), total protein, and AP with a 
toxicity grade of 1 is all owable. 
Serum chloride and albumin above the upper limit of normal (ULN) is allowable.  
If UA by [CONTACT_694364] B  for blood, protein , or glucose , a 
complete UA with microscopic evaluation will be performed and the results will supersede those 
of the dipstick. Menstruating females failing inclusion criteria due to a positive urine dipstick or 
microscopic UA may be retested following cessation of menses. Do not exc lude subjects with ≤6 
RBC/HPF . 
Laboratory  values that are outside the range of eligibility but are thought to be due to an acute 
condition or due to collection or laboratory error may be repeated once.   
Laboratory values will be transferred in AdvantageED CSM.  
Abnormal  safety laboratory values after dosing will be graded per the Toxicity Table , Appendix  
C. Abnormal values within the acceptable range per Appendix B  noted at screening or baseline 
will only be considered AEs if they deteriorate after study drug dosing.  
[IP_ADDRESS] Viral Serology Testing  
Serological testing for HIV antibody, HCV antibody, and HBsAg will be performed at Screening 
Visit. These tests must be negative  for study eligibility . In cases where a false -positive result is 
suspected, confirmatory testing (e.g., Polymerase Chain Reaction)  may be performed . 
[IP_ADDRESS] Pregnancy Testing  
In all women, a serum β -HCG level will be measured at Screening Visit and on Day -1; results 
must be negative for entry into the trial. Serum pregnancy test will also be performed at Final 
Visit, or ET. 
[IP_ADDRESS] Serum FSH testing  
A serum FSH level for confirmation of post -menopausal status in female subjects will be 
measured at Screening Visit only.   
[IP_ADDRESS] Urine Toxicology Screening  
A urine toxicology screen will be performed at Screening Visit and on Day -[ADDRESS_961715] 
be negative for study eligibility. Urine creatinine will be measured as part of the profile to assess 
quality of collected sam ple.  
DMID Protocol 16 -0118 Version 2.0 
Zoliflodacin  25 January 2018  
 ________________________________ ________________________________ ________________________________ ______  
48 [IP_ADDRESS] Alcohol testing by [CONTACT_707777] -1. Results must be negative for study eligibility.  
8.2.2 Special Assays or Procedures  
[IP_ADDRESS] Pharmacokinetics Assay  of Zoliflodac in  
Blood (plasma) samples will be collected in K2EDTA tubes at the following study days and time 
points: On Day 1  at 30 min before dosing, and 0.5  h (±5 min), 1 h (±5 min), 2 h (±5 min), 3 
h (±10 min), 4 h (±10 min), 6 h (±10 min), 8 h (±15 min), and 12 h (±15 min)  after dosing; on 
Day 2 at 24 h (± 2 h) and 36 h (± 2 h) after dosing; on Day 3 at 48 h (±2 h) after dosing; and on 
Day 4 at 72 h (±2 h) after dosing , or ET. 
Sample collections will be scheduled for the nominal time point  and actual collection times 
recorded in the source documents.  
Plasma concentrations  of zoliflodacin will be determined using a validated HPLC-MS/MS 
method. 
8.2.3 Specimen Preparation, Handling, and Shippi[INVESTIGATOR_007]  
[IP_ADDRESS] Instructions for Specimens Preparation, Handling, and Storage  
Details regarding the specimen preparation, handling, and storage are described in the protocol -
specific MOP.  
[IP_ADDRESS] Specimen Shipment  
Specimen shipment will occur at intervals during th e trial following all applicable International 
Air Transport Association (IATA) requirements and according to the specifics for storage 
temperature and documentation as detailed in the central (clinical) laboratory manual and 
protocol-specific MOP , as approp riate. 
All specimens for clinical screening and safety laboratory evaluations will be transported from 
the CTU to the local clinical laboratory.  
Plasma samples for bioanalytical assays  will be shipped from the CTU to the DMID -CMS 
(Fisher BioServices)  at: 
 
Fisher BioServices  
DMID Protocol 16 -0118 Version 2.0 
Zoliflodacin  25 January 2018  
 ________________________________ ________________________________ ________________________________ ______  
49 c/o DMID Clinical Materials Services (CMS)  
[ADDRESS_961716]  
Germantown, MD [ZIP_CODE]  
Phone: 240 -477-1350  
Fax: [PHONE_6137] 
Email: [EMAIL_5798]  
The plasma samples will then be provided by [CONTACT_122830] -CMS to the bioanalytical lab, KCAS Inc. , 
at:  
KCAS Bioanalytical Services  
[ADDRESS_961717]  
Shawnee, KS [ZIP_CODE]  
POC:  Marsha Luna  
           Senior Manager, PBI  
Office: 913 -248-3042  
Email: [EMAIL_13282]  
 
 
 
DMID Protocol 16 -0118 Version 2.0 
Zoliflodacin  25 January 2018  
 ________________________________ ________________________________ ________________________________ ______  
 
 50 9 ASSESSMENT OF SAFETY  
Regulatory requirements including FDA regulations  and ICH Guidelines for GCP set forth safety 
monitoring and reporting responsibilities of sponsors and investigators to ensure the safety  and 
protection of human subjects participating in clinical trials.  
Responsibilities : 
Investigators participating in this clinical trial are responsible for and will:  
• Evaluate subject safety including assessment of AEs for seriousness, severity, and 
causality (relatedness to study drug); 
• Notify the sponsor (DMID) of SAEs within 24 h of site awareness ; 
• Provide detailed written reports, including necessary documentation r equested by [CONTACT_366482]/EC, promptly following immediate initial reports ; 
• Inform the IRB/EC of SAEs and AEs as required by [CONTACT_25435] . 
9.1 Specification of Safety Parameters  
Safety will be assessed by [CONTACT_469421], frequency, relat edness to study drug, and severity of:  
1. Treatment-emergent SAEs occurring from dosing through Final Visit (Day 8 ± 2) , or ET; 
2. Clinical laboratory AEs occurring from  dosing through Final Visit (Day 8 ± 2) , or ET; 
3. Non-serious, unsolicited treatment -emergent AEs occurring from  dosing through Final 
Visit (Day 8 ± 2) , or ET. 
9.[ADDRESS_961718]. An AE can therefore be any unfavorable and unintended sign (including an 
abnormal laboratory find ing), symptom, or disease temporally associated with use of the product. 
The occurrence of an AE may come to the attention of study personnel during study visits and 
interviews, or by a subject presenting for medical care.  
The FDA defines an AE as any unto ward medical occurrence associated with the use of a drug in 
humans, whether it is considered drug -related or not.  
DMID Protocol [ADDRESS_961719] be graded for severity and relationship to the study drug. 
[IP_ADDRESS] Severity of Events  
Intensity o f AEs will be graded as follows , unless otherwise specified in Appendix C: 
Mild: Require minimal or no treatment ; do not interfere with the subject’s daily activities.  
Moderate:  Result in a low level of inconvenience or concern with therapeutic measures ; may 
cause some interference with functioning.  
Severe: Interrupt a subject’s usual daily activity and may require systemic drug therapy or other 
treatment ; are usually incapacitating.  
[IP_ADDRESS] Relationship to Study  Products  
AEs and SAEs must be assessed by [CONTACT_557401], 
using the following two terms. In a clinical trial , the study drug must always be suspect.   
• Related: There is a reasonable possibility that the study drug caused the AE/SAE; that is, 
there is evidence to suggest a causal relationship  
• Not Related : There is not a reasonable possibility that the  study drug caused the AE/SAE 
The investigator must provide an assessment of association or relationship of each AE/SAE to 
the study drug based on:  
• Temporal relationship of the AE/SAE to study drug dosing; 
• Whether an alternative etiology has been identified;  
• Biological plausibility;  
• Existing therapy and/or ConMeds . 
[IP_ADDRESS] Reporting Adverse Events  
AEs will be captured on the appropriate subject’s source document and eCRF. Information 
collected for AEs includes event description, time of onset, investigator assessment of severity , 
relationship to the study drug, date of resolution of the event, seriousness, and outcome.  
All AEs will be documented from the time of drug dosing up to and including Final Visit. AEs 
will be followed to resolution or until considered stable in the clini cal judgment of the study 
investigator. Evaluation of AEs may require unscheduled visits and clinical and laboratory 
investigations, according to the clinical judgment of the Site PI [INVESTIGATOR_425320].  
DMID Protocol 16 -0118 Version 2.0 
Zoliflodacin  25 January 2018  
 ________________________________ ________________________________ ________________________________ ______  
 
 52 9.2.2 Reactogenicity (for Vaccine Studies and Some Therap eutic Trials)  
Not applicable.  
9.2.[ADDRESS_961720] one of the following criteria:  
• Death; 
• Life-threatening AE*;  
• Inpatient hospi[INVESTIGATOR_1081];  
• Persistent or significant disability or incapacity, or substantial disruption of the ability to 
conduct normal life function;  
• Congenital anomaly/birth defect;  
• Important medical events that may not result in death, be life -threatening, or require 
hospi[INVESTIGATOR_128151] c onsidered an SAE when, based upon appropriate medical 
judgment, they may jeopardize the subject and may require medical or surgical 
intervention to prevent one of the outcomes listed in this definition. Examples of such 
medical events include allergic bron chospasm requiring intensive treatment in an 
emergency room or at home, blood dyscrasias or convulsions that do not result in 
inpatient hospi[INVESTIGATOR_059], or the development of drug dependency or drug abuse.  
*Life-threatening AE. An AE is considered “life -threatening” if, in the view of either the 
investigator or sponsor, its occurrence places the subject at immediate risk of death. It 
does not include an AE that, had it occurred in a more severe form, might have caused 
death. 
SAEs will be:  
• Assessed for sever ity and relationship to study product and alternate etiology  by [CONTACT_469423] (listed on FDA Form 1572) ; 
• Recorded on the appropriate SAE data collection form and eCRF ; 
• Followed through resolution ; 
• Reviewed and evaluated by [CONTACT_694368] (as deemed  necessary), the SMC (periodic review 
unless related), DMID, and the IRB.  
9.2.[ADDRESS_961721] Values or 
Abnormal Clinical Findings  
A licensed study clinician (listed on FDA Form 1572) will make the determinati on of 
seriousness, severity, and causality ; provide a medical evaluation of AEs; and classify AEs based 
upon medical judgment.  
Abnormal laboratory values or clinical findings for all enrolled subjects, including values and 
findings noted at screening and b aseline, will be assessed using the toxicity scales in Appendix 
C. Abnormal values and findings noted at screening or baseline will only be considered AEs if 
DMID Protocol [ADDRESS_961722] at the time of protocol submission are 
included in Appendix B. Changes in these ranges during the trial will be handled as 
administrative protocol amendments and toxicity grades will be calculated using the new ranges 
from the effective date of the change. A regular protocol amendment will be submitted for these 
changes if a revised laboratory normal range  value meets criteria for Grade 2 toxicity.  
Gross blood in urine that is confirmed due to a menstrual cycle is not an AE (but is for all other 
reasons). 
9.3 Reporting Procedures  
9.3.1 Serious Adverse Events  
SAEs will be followed until resolution even if this extends beyond the study -reporting period.  
Resolution of an AE is defined as the return to pretreatment status or stabilization of the 
condition with the expectation that it will remain chronic.  
All SAEs will be : 
• Recorded on the appropriate SAE report for m and sent to  DMID Pharmacovigilance 
Group (PVG) 
• Entered into the appropriate subject source document and eCRF in Advantage EDCSM 
• Reported to the Site ISM and the IRB  
• Reviewed and followed to resolution or stability by a n authorized  study physician (listed 
on FDA Form 1572)  
• Collected on each subject until Final Visit  
Any AE that meets a protocol -defined serious criterion must be submitted immediately (within 
24 h of site awareness) on an SAE report form to DMID PVG:  
 
DMID Protocol 16 -0118 Version 2.0 
Zoliflodacin  25 January 2018  
 ________________________________ ________________________________ ________________________________ ______  
 
 54  
 
DMID Pharmacovigilan ce Group 
Clinical Research Operations and Management Support (CROMS)  
[ADDRESS_961723] ive, Suite 650  
Bethesda, MD 2081 7, [LOCATION_003] 
SAE Hot Line: 1 -[PHONE_889] (US) or 1 -[PHONE_1728] (outside US)  
SAE FAX Number: 1 -[PHONE_1729] (US) or [PHONE_2621] (outside US)  
SAE Email Address: [EMAIL_1393]  
In addition to the SAE report form, selected SAE data fields must also be entered into 
AdvantageEDCSM. Please see the protocol -specific MOP for details regarding this procedure.  
Other supporting documentation of the SAE may be requested by [CONTACT_707778].  
The site will copy the ISM on SAE repor ts provided to the DMID PVG. The DMID MM and 
DMID CPM will be notified of the SAE by [CONTACT_694371]. The DMID MM will review and 
assess the SAE for regulatory reporting and potential impact on study subject safety and protocol 
conduct. 
At any time after completion of the study, if the site PI [INVESTIGATOR_29353] -investigator becomes 
aware of an SAE that is su spected to be related to study product, the site PI [INVESTIGATOR_29353] -
investigator will report the event to the DMID PVG. 
9.3.2 Regulatory Reporting for Studies Conducted Under DMID Sponsored IND  
Following notification from the investigator, DMID, the Investiga tional New Drug (IND) 
sponsor, will report any suspected AE that is both serious and unexpected. DMID will report an 
AE as a suspected AE only if there is evidence to suggest a causal relationship between the drug 
and the AE. DMID will notify FDA and all p articipating investigators (i.e., all investigators to 
whom the sponsor is providing drug under its IND(s) or under any PI’s IND(s)) in an IND safety 
report of potential serious risks from clinical trials or any other source, as soon as possible, but in 
no case later than 15 calendar days after the sponsor determines that the information qualifies for 
reporting as specified in 21 CFR Part 312.32. DMID will also notify FDA of any unexpected 
fatal or life -threatening suspected AE as soon as possible, but in n o case later than 7 calendar 
days after the sponsor’s initial receipt of the information. Relevant follow up information to an 
IND safety report will be submitted as soon as the information is available. Upon request from 
FDA, DMID will submit to FDA any a dditional data or information that the agency deems 
necessary, as soon as possible, but in no case later than [ADDRESS_961724]. 
DMID Protocol 16 -0118 Version 2.0 
Zoliflodacin  25 January 2018  
 ________________________________ ________________________________ ________________________________ ______  
 
 55 All serious events designated as “not related” to  the study drug, will be reported to the FDA at 
least annually in a summary format . 
9.3.3 Other Adverse Events (if applicable)  
[IP_ADDRESS] Reporting of Overdose  
An overdose is defined as a dose greater than the high -dose level evaluated in the trial as 
described in Section 6.3.1 of the protocol. All overdoses should be reported; if the overdose is 
associated with an AE, then the AE should also be reported. In the event of an overdose of study 
drug, the investigator  should use clinical judgment in treating the overdose and contact [CONTACT_707779]. The investigator should refer to the relevant document(s) for detailed information 
regarding warnings, precautions, contraindications, AEs, and other significant data pertainin g to 
zoliflodacin. Such documentation may include but not be limited to the IB.  
9.3.[ADDRESS_961725]’s permission , all protocol -
required venous blood samples will be obtained and the subject will continue to be followed for 
safety until Final Visit. Efforts will be made to follow all pregnancies reported during th e trial to 
pregnancy outcome, as d escribed in the protocol-specific MOP (e.g. , delivery, spontaneous 
abortion, or therapeutic abortion), pending the subject’s permission.  
A female subject who participates in the trial and becomes pregnant will be asked to inform 
study personnel of a pregna ncy occurring [ADDRESS_961726]'s source 
document and eCRF. 
DMID Protocol [ADDRESS_961727] be stopped  and a review of available safety data will be conducted by [CONTACT_707780] 1 after dosing : 
1. Death of a  subject following dosing regardless of relatedness to study drug;  
2. One subject with an SAE that is considered related to study drug by [CONTACT_9154] [INVESTIGATOR_707752] ; 
3. Two or more subjects with a Grade  3 systemic AE coded in the same organ system that is 
considered related to the study  drug by [CONTACT_9154] [INVESTIGATOR_707753] (listed in FDA 
Form 1572) ; 
Note: VS abnormalities should be considered part of a systemic disorder or an organ -
specific condition, as described in Appendix C , in order to be included among the 
Study Halting Criteria .  
4. An overall pattern of symptomatic, clinical non-serious events that the study PI [INVESTIGATOR_707754] s, but that may collectively represent a serious potential safety 
concern and pose a risk to continuing the subject in the trial. 
9.6 Safety Oversight  (ISM plus SMC)  
9.6.1 Independent Safety Monitor  (ISM) 
The ISM is a physician with relevant expertise whose primary responsibility is to provide 
independent safety m onitoring in a timely fashion. The ISM will review SAEs and other AEs as 
needed and provide an independent assessment to DMID.  
9.6.2 Safety Monitoring Committee  (SMC) 
Safety oversight will be conducted by a SMC , which is an independent group of experts that 
monitors subject safety and advises DMID. SMC members will be separate and independent of 
study personnel participating in th e trial and should not have scientific, financial , or other 
conflicts of interest related to th e trial. The SMC will consist of members with appropriate 
expertise to contribute to the interpretation of the data from th e trial. 
The SMC will meet as follows:  
• Organizational meeting ( before study initiation) 
• Ad hoc meeting 
o When study halting criteria are met  
o At the request of DMID to review a potential safety concern identified by [CONTACT_707781], ISM, or DMID MM  
DMID Protocol 16 -0118 Version 2.0 
Zoliflodacin  25 January 2018  
 ________________________________ ________________________________ ________________________________ ______  
 
 57 • Scheduled  meeting 
o The SMC will review all available safety data when available  
Procedures for SMC reviews/meet ings will be defined in the SMC charter. The SMC will review 
safety data and advise on using the 4-g dose of zoliflodacin  in a subsequent thorough QT study . 
DMID Protocol [ADDRESS_961728] protection s, study and laboratory 
procedures, study intervention administration, and data collection processes are of high quality 
and meet sponsor, GCP/ICH , and regulatory guidelines , when appropriate . Site visits may be 
conducted by [CONTACT_707782], subjects’ medical records, and eCRFs in accordance with ICH guidelines, GCP , and the 
respective local and national government regulations and guidelines.  
The investigator will perm it authorized representatives of DMID and the respective local and 
national health authorities to inspect facilities and records relevant to th e trial, if needed.  
A separate monitoring plan  developed by [CONTACT_469433] -specific items to be 
monitored. 
Site visits will be made at standard intervals defined by [CONTACT_469434]. Monitoring visits will include , but not be limited to , review of regulatory 
files, accountability records, subject’s source  documents, eCRFs, ICFs, clinical and laboratory 
reports, and protocol and GCP compliance. Site monitors will have access to each participating 
site, study personnel, and all study docume ntation according to the DMID -approved site 
monitoring plan. Study monitors will meet with the Site PI [INVESTIGATOR_707755].  
 
DMID Protocol 16 -0118 Version 2.0 
Zoliflodacin  25 January 2018  
 ________________________________ ________________________________ ________________________________ ______  
 
 59 11 STATISTICAL CONSIDER ATIONS  
11.1 Study Hypotheses  
There are no fo rmal hypotheses being tested in this Phase 1 trial. The objectives of the trial are to 
obtain additional PK and safety data for a single 4 -g oral dose of zoliflodacin.  
11.1.1 Study Objectives and Outcome Measures  
[IP_ADDRESS] Study Objectives  
Primary Objective:   To evaluate t he plasma PK of a single 4 -g oral dose of zoliflodacin 
under fasting conditions  
Secondary Objective :  To evaluate the safety and tolerability of a single 4 -g oral dose of 
zoliflodacin  
[IP_ADDRESS] Study Outcome Measures  
Primary Endpoints:   Cmax, Tmax, AUC (0-last), and other PK parameters determined using 
plasma concentrations of zoliflodacin in blood samples collected on Day 1 [baseline (30 
min before dosing) and 0.5 h, 1 h , 2 h , 3 h , 4 h , 6 h , 8 h , and 12 h  after dosing], Day 2 
[24 h and 36 h after  dosing], Day 3 [48 h after dosing], and Day 4 [72 h after dosing], or 
ET, and measured using a validated HPLC -MS/MS method  
Secondary Endpoints:  
• The occurrence of treatment -emergent SAEs from administration of zoliflodacin on 
Day 1 to Final Visit  (Day 8 ± 2), or ET 
• The occurrence of unsolicited AEs from administration of zoliflodacin on Day 1 to 
Final Visit (Day 8 ± 2) , or ET 
• The changes from baseline (up to 60 min before dosing) in VS following 
administration of zoliflodacin as measured on Day 1 [1 h, 2 h, and 4 h after dosing], 
Days 2, 3 and 4 [24 h, 48 h, and 72 h, respectively, after dosing], and Final Visit (Day 
8 ± 2) , or ET 
• The changes from baseline (tested on Day -1) in clinical laboratory test values 
following administration of zoliflodacin, as measured on Day 4 [72 h after dosing], or 
ET 
• The changes from baseline (up to 60 min before dosing) in ECG parameters 
following  administration of zoliflodacin, as measured on Day 1 [1 h, 2 h, and 4 h after 
dosing] and Day 4 [72 h after dosing], or ET  
DMID Protocol [ADDRESS_961729] of the trial. A scheduled SMC meeting 
will be held after all subjects complete the trial to review safety data, and advice on  using the 4 -g 
dose in a subsequent thorough QTc study. If criteria for halting the trial (as listed in Section 
9.5.1) are met during dosing on Day 1, an ad hoc SMC meeting will be held to review all 
available safety data and to make recommendations about the dosing of all further subjects in the 
trial. 
11.4 Final Analysis Plan  
The ICH/ FDA Guidance Document E9 (Statistical Principles for Clinical Trial s) will be 
followed for all statistical content.[ADDRESS_961730] deviation, and maximum. Details of study analyses for safety and PK data and 
their presentation will be described in the Statistical Analysis Plan (SAP) and accompanying 
Tables, Listings and Figur es (TLF) templates. The SAP will be prepared and finalized by [CONTACT_707783]. Analyses included in the CSR will be performed by [CONTACT_707784]. Any change from originally planned statistical analyses will be reported in the  
final clinical study report (CSR).    
11.4.[ADDRESS_961731] demographics and baseline characteristics will be summarized. The number of subjects 
who enroll in the trial, and the number and percentage of subjects who complete each 
assessment , will be presented. The percentage of subjects who withdraw fr om the trial or 
discontinue the study drug,  and reason s for withdrawal or discontinuation , will be summarized.  
11.4.3 Safety Analysis Plan  
[IP_ADDRESS] Adverse and Serious Adverse Events  
AEs will be coded using the latest version of the Medical Dictionary for Regulatory Activities® 
(MedDRA). All AEs occur ring after study drug dosing will be summarized using frequency 
counts and percentages.  The following summaries will be presented for AEs and SAEs:  
• Overall (i.e., regardless of severity or relationship to trea tment); 
• By [CONTACT_86953] (mild, moderate, or severe) ; 
• By [CONTACT_8792]; 
• By [CONTACT_92255] (system organ class [SOC], higher level group term [HLGT], 
and preferred term [PT]) . 
Unless otherwise specified, at each level of subject summar ization in reporting the incidence of 
AEs, a subject will be counted once if the subject reported one or more AEs. If more than one 
occurrence of an AE is reported, the AE of the worst severity or the worst -case relationship 
assessment will be summarized.  
[IP_ADDRESS] Additional Safety Analyses  
Descriptive summary statistics  (mean, standard deviation, median, min, and max)  for clinical 
laboratory data, ECG parameters , and VS at admission and each applicable post -dosing visit, 
including change s from baseline value s, will be calculated. If multiple baseline values are 
obtained, only the most recent value will be analyzed. For change from screening summaries, 
subjects with an un defined change from screening, because of missing data, will be excluded.  
Clinical significance of abnormalities will be indicated in the listings.  
11.4.4  PK Analysis Plan  
PK parameters will be estimated for zoliflodacin  by [CONTACT_707785] n 
6.4 or higher of Phoenix® WinNonlin®. When evaluable, estimated PK parameters will include:  
• AUC(0-last):  Area under the concentration time -curve from time zero to the last 
concentration above the lower limit of quantitation  
• AUC(0-∞): Area under the conc entration time -curve from time zero to infinity  
• AUC(0-t: Area under the concentration time -curve from time zero to time t  
• Cmax: Maximum observed concentration  
DMID Protocol 16 -0118 Version 2.0 
Zoliflodacin  25 January 2018  
 ________________________________ ________________________________ ________________________________ ______  
 
 62 • Tmax: Time of maximum observed concentration  
• Ke: Elimination rate constant  
• t1/2: Terminal elimination half -life 
• CL/F: Apparent oral clearance  
• Vz/F: Apparent volume of distribution  
Other PK parameters may be calculated, as appropriate. Linearity of terminal elimination slope 
will be assessed statistically by [CONTACT_142031], which pro vides estimates for the slope, 
intercept, and r2 (or adjusted r2) to calculate elimination rate constant, and helps define goodness 
of fit. Details will be provide d in the SAP.  
The results will be listed by [CONTACT_1130], and summarized with descriptive statisti cs including: n, 
mean, standard deviation , coefficient of variation ( CV %), median, minimum, maximum, 
geometric mean , and geometric standard deviation .  
Graphical presentations of concentration vs. time profiles will be provided for zoliflodacin , and 
will include individual subject and mean concentration profiles.  Semi-log concentration profiles 
will be provided for individual subjects.  
11.4.[ADDRESS_961732] all data per protocol.  No imputation will be performed for 
missing values. Outliers will not be excluded from the primary analyses. Outliers identified 
during the PK analysis will be discussed in the analysis report. 
DMID Protocol 16 -0118 Version 2.0 
Zoliflodacin  25 January 2018  
 ________________________________ ________________________________ ________________________________ ______  
 
 63 12 SOURCE DOCUMENTS AND  ACCESS TO SOURCE 
DATA/DOCUMENTS  
The site will maintain appropriate medical and /or research records for th e trial, in compliance 
with ICH E6 GCP, Section 4.9, and regulatory and institutional requirements for the protection 
of confidentiality of subjects. As part of participating in a DMID -sponsored, DMID -affiliated, or 
manufacturer -sponsored trial, the site will permit authorized representatives of the sponsor 
(DMID), to include Emmes (the DCC), DynPort Vaccine Company , LLC (DVC), and regulatory 
agencies to review (and, when required by [CONTACT_1289], to copy) clinical records for the 
purposes of quality assurance reviews, audits, and evaluation of the study safety and progress.  
Forms for use as source documents will be derived from eCRFs and will be provided by [CONTACT_707786] . Additional source data are all information, original records of clinical 
findings, observations, or other activities in a clinical trial necessary for the reconstruction and  
evaluation of the trial. Examples of these original documents and data records include, but are 
not limited to, hospi[INVESTIGATOR_1097], clinical and office charts, laboratory notes, memoranda, 
pharmacy dispensing records, recorded data from automated instrument s, copi[INVESTIGATOR_19093], microfiches, photographic negatives, 
microfilm or magnetic media, x -rays, ECG print-outs, and subject files and records kept at the 
pharmacy, laboratories, and medico -technical departments involved in the clinical trial.  
 
DMID Protocol [ADDRESS_961733] access to the CTU, source 
data/documents, and reports for monitoring and auditing by [CONTACT_456], and inspection by [CONTACT_12291]. The PI [INVESTIGATOR_707756] l study personnel are appropriately trained and 
applicable documentations are maintained on site.  
The DCC will implement quality control procedures beginning with the data entry system and 
generate data quality control checks that will be run on the datab ase. Any missing data or data 
anomalies will be communicated to the site(s) for clarification and resolution.  
DMID Protocol 16 -0118 Version 2.0 
Zoliflodacin  25 January 2018  
 ________________________________ ________________________________ ________________________________ ______  
 
 65 14 ETHICS/PROTECTION OF  HUMAN SUBJECTS  
14.[ADDRESS_961734]  
The PI [INVESTIGATOR_71466] e study is conducted in full conformity with principles of the Belmont 
Report: Ethical Principles and Guidelines for the Protection of Human Subjects of Research of 
the National Commission for the Protection of Human Subjects of Biomedical and Behavioral 
Research (April 18, 1979) and codified in 45 CFR 46, 21 CFR 50 and 56, and ICH E6; 62 
Federal Regulations 2569 2 (1997), if applicable. The PI’s institution will hold a current Federal 
Wide Assurance (FWA) issued by [CONTACT_707787]-funded 
research. 
14.[ADDRESS_961735]  
The CTU will provide for the review and approval of this protocol and the associated ICFs by [CONTACT_153691] /EC listed on the FWA. Any amendments to the protocol or consent materials 
must also be ap proved before they are use d, unless change i s for the safety of the subject.  Only 
those IRB members who are independent of the investigators and the sponsor should provide an 
opi[INVESTIGATOR_230291] -related matters. Verification of IRB approval of the protocol an d the written 
ICF will be transmitted by [CONTACT_707788]. No 
deviations from or changes to the protocol will be initiated without prior approval of an 
appropriate amendment unless change is for the safety of t he subject.  
14.[ADDRESS_961736] inform subjects that the trial involves research, and explain the purpose of the 
trial, those aspects of the trial that are experimental, any expected benefits, all possible risks 
(including a statement that the particular treatment o r procedure may involve risks to the subject 
or to the embryo or fetus, if the subject is or may become pregnant, that are currently 
unforeseeable), the expected duration of the subject’s participation in the trial, the procedures of 
the research study, in cluding all invasive procedures, and the probability for random assignment 
DMID Protocol [ADDRESS_961737] (e.g., the investigator) for 
answers to any questions relating to the research project. Information will a lso include the 
foreseeable circumstances and/or reasons under which the subject’s participation in the trial may 
be terminated. The subjects must be informed that participation is voluntary and that they are 
free to withdraw from the trial for any reason at any time without penalty or loss of benefits to 
which the subject is otherwise entitled.  
Neither the investigator, nor the trial staff, should coerce or unduly influence a subject to 
participate or continue to participate in the trial. The extent of the  confidentiality of the subjects’ 
records must be defined, and subjects must be informed that applicable data protection 
legislation will be followed. Subjects must be informed that the monitor(s), auditor(s), IRB, 
NIAID, and regulatory authority(ies) will  be granted direct access to the subject’s original 
medical records for verification of clinical trial procedures and/or data without violating the 
confidentiality of the subject, to the extent permitted by [CONTACT_4913], and 
that, by [CONTACT_2960] a written ICF, the subject is authorizing such access. Subjects must be informed 
that records identifying the subject will be kept confidential, and, to the extent permitted by [CONTACT_3999]/or regulations, will not be made publicly available and, if the results of the 
trial are published, the subject’s identity will remain confidential.  
ICFs must be in a language fully comprehensible to the prospective subjects. Informed consent 
shall be documented us ing a written consent fo rm approved by [CONTACT_469440]. The signature 
[CONTACT_707794]’s satisfaction. Each subject’s signed ICF must be 
kept on file by [CONTACT_707789]/or the 
sponsor and regulatory compliance persons. The subject should receive a copy of the signed a nd 
dated written ICF and any other written information provided to the subjects, and should receive 
copi[INVESTIGATOR_707757].  
DMID Protocol 16 -0118 Version 2.0 
Zoliflodacin  25 January 2018  
 ________________________________ ________________________________ ________________________________ ______  
 
 67 14.4 Exclusion of Women, Minorities, and Children (Special Populations)  
Children under age [ADDRESS_961738] to gender or race. It is expected that race and gender 
distributions in this study will approximate the proportion to their numbers within the 
community.    
Women of childbearing potential will be included but will be repeatedly counseled to use 
effective measures ( Section 5.1) to avoid becoming preg nant from the time of screening until [ADDRESS_961739] party without prior written approval from the sponsor.  This information and 
data will not be us ed by [CONTACT_7910] [INVESTIGATOR_707758] e trial. These restrictions do not apply to: (1) information which becomes publicly 
available through no fault of the Site PI [INVESTIGATOR_29355]; (2) information which  is 
necessary to disclose in confidence to an IRB solely for the evaluation of th e trial; (3) 
information which is necessary to disclose in order to provide appropriate medical care to a study 
subject; or (4) study results which may be published as describ ed in Section 16. 
The study monitor s or other authorized representatives of the sponsor may inspect all documents 
and records required to be maintained by [CONTACT_737], including, but not limited to, medi cal 
records (office, clinic, or hospi[INVESTIGATOR_307]) and pharmacy records for the subjects in th e trial. The CTU 
will permit access to such records.  
14.6 Study Discontinuation  
DMID has the right to terminate th e trial or the site’s participation at any time. Reasons for 
terminating the trial may include, but are not limited to:  
• Incidence or severity of AEs indicates a potential health hazard  
• Data recording is inaccurate or incomplete  
DMID Protocol 16 -0118 Version 2.0 
Zoliflodacin  25 January 2018  
 ________________________________ ________________________________ ________________________________ ______  
 
 68 • Investigator does not adhere to the protocol or applicable regulatory guidelines in 
conducting the trial  
If the trial is discontinued, subjects who have signed the ICF and received the study drug will 
continue to be followed for safety for the duration of th e trial. No further study treatments will be 
administered  to other subjects . 
DMID Protocol [ADDRESS_961740] enrolled in th e trial. Data reported in the eCRF derive d 
from source documents should be consistent with the source documents or the discrepancies 
should be explained.  
DMID and/or its designee will provide guidance to investigators and other study personnel on 
making corrections to the data collection forms , source documents , and eCRFs.  
15.[ADDRESS_961741] maint ain complete and accurate documentation 
for the trial. 
Emmes will serve as the DCC for the trial, and will be responsible for data management, quality 
review, analysis, and reporting of the study data.  
15.2 Data Capture Methods  
Clinical data (including , but not limited to  AE/SAEs, ConMeds , MH, and PE) and clinical 
laboratory data will be entered into a 21CFR11 -compliant Internet Data Entry System provided 
by [CONTACT_15791]. The data system includes password protection and internal quality checks  (e.g., 
automatic range checks) to identify data that appear inconsistent, incomplete, or inaccurate. 
Clinical data will be entered directly from the data collection forms completed by [CONTACT_71510].  
15.3 Types of Data  
Data for th e trial will include clinical safety assessments, laboratory safety assessments, and PK  
parameters . 
DMID Protocol 16 -0118 Version 2.0 
Zoliflodacin  25 January 2018  
 ________________________________ ________________________________ ________________________________ ______  
 
 70 15.4 Timing/Reports  
A final CSR will be prepared after all safety and PK data are available . See Section 9.6.[ADDRESS_961742] elapsed since the formal discontinuation of 
clinical development of the study drug . These documents should be retained for a longer period, 
however, if required by [CONTACT_427]. No records will be destroyed without the written 
consent of the sponsor, if applicable. It is the sponsor’s  responsibility to inform the inve stigator 
when these documents no longer need to be retained.  
15.[ADDRESS_961743], the 
investigator, or the study site staff. Corrective actions for protocol deviations are to be developed 
by [CONTACT_3483].  
These practices are consistent with ICH E6:  
4.5 Compliance with Protocol, Sections 4.5.1, 4.5.2, and 4.5.3 
5.1 Quality Assurance and Quality Control, Section 5.1.1  
5.20 Noncompliance, Sections 5.20.1, and 5.20.2.  
It is the responsibility of the Site PI/study staff to use continuous vigilance to identify and report 
deviations within [ADDRESS_961744] be promptly reported to 
DMID via DCC’s AdvantageEDCSM. 
All protocol deviations, as defined above, must be addressed in study subj ect source documents. 
A completed copy of the DMID Protocol Deviation Form must be maintained in the regulatory 
file, as well as in the subject's source document. Protocol deviations must be sent to the local 
IRB/EC per their guidelines. The Site PI/study staff is responsible for knowing and adhering to 
their IRB requirements.  
DMID Protocol 16 -0118 Version 2.0 
Zoliflodacin  25 January 2018  
 ________________________________ ________________________________ ________________________________ ______  
 
 71 16 PUBLICATION POLICY  
Following completion of the trial, the investigator is expected to publish the results of this 
research in a scientific journal. The International Committe e of Medical Journal Editors (ICMJE) 
member journals have adopted a trials -registration policy as a condition for publication. This 
policy requires that all clinical trials be registered in a public trials registry such as 
ClinicalTrials.gov*, which is spo nsored by [CONTACT_1055] , on or before 
subject enrollment . Other biomedical journals are considering adopting similar policies. It is the 
responsibility of DMID to register th e trial in an acceptable registry.  
The ICMJE defines a clinical  trial as any research project that prospectively assigns human 
subjects to intervention or comparison groups to study the cause -and-effect relationship between 
a medical intervention and a health outcome. Studies designed for other purposes, such as to 
study PK or major toxicity (e.g., Phase I trials), are exempt from this policy.  
1. *Journal Citation:  
De Angelis C, Drazen JM, Frizelle FA, Haug C, Hoey J, Horton R, et al. Clinical trial 
registration: a statement from the International Committee of Medical Jou rnal Editors. N 
Engl J Med. 2004; 351:1250 -1. 
 
DMID Protocol 16 -0118 Version 2.0 
Zoliflodacin  25 January 2018  
 ________________________________ ________________________________ ________________________________ ______  
 
 72 17 LITERATURE REFERENCE S 
1. Unemo M, Nicholas RA. Emergence of multidrug –resistant, extensively drug resistant  
and untreatable gonorrhea. Future Microbiol 2012;7(12):[ADDRESS_961745] Dis Clin North Am 2013;27(4):723 -37 
 
3. World Health Organization, Department of Reproductive Health and Research.  
Global incidence and prevalence of selected curable sexually trans mitted infections - 
2008. Available at:  
http://www.who.int/reproductivehealth/publications/rtis/stisestimates/en/index.html   
(accessed on 10 July 2014)  
 
4. Centers for Disease Control and Prevention, (CDC). CDC Fact Sheet: STD Trends in  
the [LOCATION_002]: 201 1 National Data for Chlamydia, Gonorrhea, and Syphilis, 2013.  
Available at: http://www.cdc.gov/std/stats11/trends -2011.pdf  (accessed on 10 July  
2014) 
 
5. Centers for Disease Control and Prevention (CDC). Antibiotic Resistance Threats in  
the [LOCATION_002], 20 13. Available at: https://www.cdc.gov/drugresistance/threat -report-
2013/pdf/ar -threats-2013-508.pdf (accessed on 10 July 2014)  
 
6. Unemo M, Shafer WM. Antibiotic resistance in Neisseria gonorrhoeae: origin,  
evolution, and lessons learned for the future. Ann N  Y Acad Sci 2011;1230:E19 -28 
 
7. World Health Organization. Antimicrobial resistance: global report of surveillance - 
2014. Available at:  
http://apps.who.int/iris/bitstream/[ZIP_CODE]/112642/1/9789241564748_eng.pdf   (accessed  on 
10 July 2014 )  
 
8. Investigator’s  Brochure. Product Name,  Zoliflodacin (Research number ), 
 
 
9. Basarab GS, Kern GH, McNulty J, et al. Responding to the challenge of untreatable 
gonorrhea: ETX0914, a first -in-class agent with a distinct mechanism -of-action against 
bacterial Type II topoisomerases. Sci Rep. 2015 Jul 14;5:[ADDRESS_961746] PA, Otters on LG, et al. In vitro antibacterial activity of AZD0914, 
a new spi[INVESTIGATOR_694337]/topoisomerase inhibitor with potent activity 
against Gram -positive, fastidious Gram -Negative, and atypi[INVESTIGATOR_213562]. Antimicrob 
Agents Chemother. 2015 Jan; 59( 1): 467-74. 
  

DMID Protocol 16 -0118 Version 2.0 
Zoliflodacin  25 January 2018  
 ________________________________ ________________________________ ________________________________ ______  
 
 73 11. Su X-H, Wang B -X, Le W-J, et al. Multidrug -Resistant Neisseria gonorrhoeae Isolates 
from Nanjing, China, Are Sensitive to Killing by a Novel DNA Gyrase Inhibitor, 
ETX0914 (AZD0914). Antimicrob Agents Chemother. 2016 Jan; 60(1): 621 –623 
 
12. A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD0914 (Phase 1 
study). Study Registry ID: [REMOVED] . 
https://clinicaltrials.gov/ct2/show/[STUDY_ID_REMOVED]?term=AZD0914&rank=3  (accessed 
27July 2017). 
 
13. Randomized, Open -label Phase 2 Study of Oral AZD0914 in the Treatment of 
Gonorrhea. Study Registry ID: [REMOVED].  
https://clinicaltrials.gov/ct2/show/[STUDY_ID_REMOVED]?term=AZD0914&rank=1  (accessed 27 
July 2017  
 
14. Guidance for Industry. E14:  Clinical Evaluation of QT/QTc Interval Prolongation and 
Proarrhythmic Potential for Non -Antiarrhythmic Drugs. FDA, October 2005. 
https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guid
ances/UCM073153.pdf  (Accessed on 27 July 2017)  
 
15. U.S. Medical Eligibility Crit eria for Contraceptive Use, 2016. CDC MMWR 65: (3): 1 -
108, 2016  
 
16. Guidance for Industry. E9 Statistical Principles for Clinical Trials. FDA, September 
1998. 
https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidan
ces/ucm073137.pdf  (accessed on 27 July 2017)  
 
  
 
 
 
DMID Protocol 16 -0118 Version 2.0 
Zoliflodacin  25 January 2018  
 ________________________________ ________________________________ ________________________________ ______  
 
 74 18 APPENDICES
DMID Protocol 16 -0118 Version 2.0 
Zoliflodacin  25 January 2018  
 ________________________________ ________________________________ ________________________________ ________________________________ _____________   
 
 ________________________________ ________________________________ ________________________________ ________________________________ _____________   
  75 APPENDIX A: SCHEDULE  OF STUDY PROCEDURES AND  EVALUATIONS  
Study Visit  Screening  1 Check-in Inpatient Period 
Final Visit Unscheduled  Early 
termination  Dosing Follow Up  
Study Day / Assessments  -21 to -2 -1 1 2 3 4 8 (± 2)   
Informed consent X         
Inclusion/Exclusion criteria X X X       
Demographics  X         
Medical history X         
Medical history update   X X X X X X X X 
Prior and ConMeds  2 X X X X X X X X X 
Complete PE  3 X      X  X 
Abbreviated PE  4  X    X    
Symptom -directed PE  5   X X X   X  
Height, weight, BMI 6 X         
Weight  X     X   
Vital signs 7 X X X X X X X X X 
Clinical labs (HEM, 
CHEM, UA) [ADDRESS_961747] X X        
12-lead ECG 10 X X X   X   X 
Study drug dosing   X       
PK samples 11   X X X X   X 
Counsel on use of 
contraception and 
avoidance of pregnancy14 X     X X  X 
DMID Protocol 16 -0118 Version 2.0 
Zoliflodacin  25 January 2018  
 ________________________________ ________________________________ ________________________________ ________________________________ _____________   
 
 ________________________________ ________________________________ ________________________________ ________________________________ _____________   
  76 Study Visit  Screening  1 Check-in Inpatient Period 
Final Visit Unscheduled  Early 
termination  Dosing Follow Up  
Study Day / Assessments  -21 to -2 -1 1 2 3 4 8 (± 2)   
Counsel to avoid use of 
prohibited medications, 
alcohol, marijuana and 
illicit drugs  X X    X X   
Interim medical history    X X X X X X X 
AE and SAE review 12   X X X X X X X 
Admit to CTU   X        
Discharge from CTU       X    
Discharge from trial        X   
 
1. Screening Visit is completed within 21 days before study drug dosing and may require more than one visit.  
2. Prior medications include prescription drugs taken 30 days before dosing, and non-prescription drugs, herbs, vitamins, and nutritional supplements  taken 15 days before 
dosing. Concomitant medications include those taken after dosing.  
3. Complete PE (except g enital, breast, and rectal exam): at Screening, and Final Visit, or ET.  
4. Abbreviated PE: on Day  -1 (not performed if the complete PE was performed ≤7 days from this visit) and Day 4 . 
5. Symptom -directed PE: on Days 1  (predose and postdose) , 2, and [ADDRESS_961748] -dose. 
6. BMI is calculated as wt (kg) / ht (m2). 
7. Vital Signs (BP, HR, RR, T): at Screening  Visit; on Days -1, 1, 2, 3, and 4 ; and at Final Visit, or ET. On Day 1 , VS at baseline (approximately 1 h before dosing) and at 1 h (±5 
min), 2 h (± 10 min), and 4 h (±10 min) after dosing . 
8. Clinical laboratory testing  with minimum [ADDRESS_961749] : HEM (Hgb, Hct, RBC, WBC with differential absolute count, platelet count); CHEM ( creatinine with estimation of GFR , 
BUN, glucose, total bilirubin, direct bilirubin, AST, ALT, AP, total protein, albumin, electrolytes (sodium, potassium, chloride, bicarbonate  (CO2), magnesium); and dipstick 
UA (blood, protein, glucose): at Screening, Day  -1 (if not collected ≤7 days before dosing), Day 4 , or ET. 
9. Viral Serology (HIV antibody, HBsAg, HCV antibody): at Screening  Visit. 
10. 12-lead ECG with 10 sec rhythm strip: at Screening  Visit, Day -1, Day 1 [within 1 h  before dosing, and at 1 h (±10 min), 2 h (± 10 min), and 4 h (±10 min) after dosing ], and 
Day 4 [72 h (±2 h) ] after dosing, or ET . 
11. Blood (plasma) PK samples: within 30 min before  dosing , and at 0.5 h (±5 min), 1 h (±5 min), 2 h (± 5 min), 3 h (±10 min), 4 h (±10 min), 6 h (±10 min), 8 h (± 15 
min), 12 h (± 15 min), 24 h (± 2 h), 36 h (± 2 h), 48 h (± 2 h), and 72 h (± 2 h) after dosing, or ET . 
12. Collect all AEs from the time of dosing to and including Final Visit. Follow -up AEs and SAEs t o resolution  or stabilization in the clinical judgment of the 
study investigator .  
13. Serum pregnancy test in all women. FSH only in post -menopausal women.  
14. Females to use appropriate contraception and avoid pregnancy to [ADDRESS_961750] study visit.   
DMID Protocol 16 -0118 Version 2.0 
Zoliflodacin  25 January 2018  
 ________________________________ ________________________________ ________________________________ ______  
 
 ________________________________ ________________________________ ________________________________ ______  
77 
  APPENDIX B: ACCEPTAB LE RANGES OF SCREENI NG 
LABORATORY AND VITAL  SIGN MEASUREMENT S  
HEMATOLOGY AND CHEMISTRY  
 
Lab test name  [CONTACT_707795] (Hgb), male  14-18 13.5 18.5 g/dL 
Hemoglobin (Hgb), female  12-15 11.5 16.5 g/dL 
Hematocrit (Hct), male  42-52 40 54 % 
Hematocrit (Hct), female  37-47 35 49 % 
White blood cell count (WBC)  4-11 3.5 11.5 x103/µL 
Neutrophil count  1.4-8.2 1.2 8.5 x103/µL 
Lymphocyte count  1-4.8 0.8 5 x103/µL 
Monocyte count  0-0.9 0 1.1 x103/µL 
Eosinophil count  0-0.3 0 0.6 x103/µL 
Basophil count  0-0.2 0 0.3 x103/µL 
Platelet count  150-400 125 475 109/L 
Sodium 137-145 132 148 mmol/L 
Potassium  3.5-5.1 3.3 5.3 mmol/L 
Bicarbonate  (CO2) 22-30 20 32 mmol/L 
Chloride 98-107 94 115 mmol/L 
Calcium  8.4-10.2 8.0 11.0 mg/dL 
Magnesium  1.6-2.3 1.1 2.8 mg/dL 
Blood urea nitrogen (BUN)  7-20 0 25 mg/dL 
Phosphorous  2.5-4.5 2.3 4.8 mg/dL 
Glucose, fasting 74-106 50 120 mg/dL 
Serum creatinine  0.5-1.3 <0.5 1.4 mg/dL 
Direct Bilirubin  0.0-0.4 0 0.5 mg/dL 
Total bilirubin  0.2-1.3 0 1.5 mg/dL 
Total protein  6.3-8.2 6.0 8.6 g/dL 
Albumin 3.5-5.0 3.2 6.0 g/dL 
Aspartate transferase (AST)  3-42 0 46 U/L 
Alanine transferase (ALT), male  21-72 0 80 U/L 
Alanine transferase (ALT), female  10-44 0 50 U/L 
Alkaline phosphatase  38-126 0 150 U/L 
Hepatitis B surface antigen  non-reactive non-reactive non-reactive  n/a 
Hepatitis C antibodies  non-reactive non-reactive non-reactive  n/a 
HIV test non-reactive non-reactive non-reactive  n/a 
Serum β-HCG (females only)  negative negative negative  n/a 
FSH (post -menopausal)  21.5-131 21.5 131 mIU/mL 
DMID Protocol 16 -0118 Version 2.0 
Zoliflodacin  25 January 2018  
 ________________________________ ________________________________ ________________________________ ______  
 
 ________________________________ ________________________________ ________________________________ ______  
78 
   
Footnotes: Exceptions to screening laboratory tests’ normal reference ranges are:  
 
a. Racially-based low total WBC or neutrophil counts up to toxicity Grade 1 in Appendix C Toxicity Tables , are allowed, but 
toxicity Grades 2 or 3 are exclusionary.  
b. Abnormalities in mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin 
concentration (MCHC), red cell distribution width (RDW), mean platelet volume (MPV), and nucleated red blood cell count 
(NRBC CT), which are included in a CBC with differential, will not be exclusionary. The re sults will be included in the database 
for comparison with results obtained as a part of safety laboratory tests.  
c. Abnormalities in serum creatinine, BUN, total bilirubin, AST, ALT, and chloride below the lower limit of normal (LLN) are 
allowable.  
d. Elevated bilirubin due to documented Gilbert’s syndrome that is Grade 1 is allowable, but Grade 2 or higher is exclusionary. (To 
document a subject has Gilbert syndrome, a diagnosis from the medical record must be provided or PI [INVESTIGATOR_114307] a ‘presumptive’ 
diagnosis of Gilbert syndrome in subjects with unconjugated hyperbilirubinemia on repeated testing (at least two samples 
separated in time) who have otherwise normal serum ALT, AST, and AP conc entrations, and a normal CBC.  
e. Elevated serum glucose, sodium, potassium, bicarbonate  (CO2), total protein, and AP, with toxicity Grade 1 values, are allowable.  
f. Serum chloride and albumin above the upper limit of normal (ULN) is allowable.  
g. Other laboratory  values that are outside the range of eligibility but are thought to be due to an acute condition or due to collection 
or laboratory error may be repeated once.   
 
 
 
 
  
DMID Protocol [ADDRESS_961751] name  [CONTACT_707796] 1+ b  
Blood negative negative trace b  
Glucose negative negative trace b  
Urine Microscopy  
WBCs in urine 
(sediment)  0-5 0 6 /field 
RBCs in urine 
(sediment)  0-5 0 6 /field 
Bacteria negative few b /field 
Hyaline casts  0.5 none trace b /field 
Crystals none 0 b  
Footnotes:   
a (1) If UA by [CONTACT_92223], a complete UA with microscopic evaluation will be performed and the 
results will supersede the results of the dipstick.  
(2) Menstruating females failing inclusion criteria due to a positive blood on a urine test (dipstick or 
microscopic UA) may be retested following cessat ion of menses. Do not exclude female subjects with  ≤ 
6 RBC/HPF . 
b Per investigator judgment, based on medical history . 
 
  
DMID Protocol [ADDRESS_961752] be negative for all tested substances (amphetamines, cocaine (and metabolite), 
barbiturates, benzodiazepi[INVESTIGATOR_1651], opi[INVESTIGATOR_858], tetrahydrocannabinol, methamphetamines, 
methadone, TCA, MDMA, and phencyclidine). Urine creatinine will be measured as part of 
the profile to assess quality of collected sample.  
 
VITAL SIGNS  
 
Measurement  lower limit  upper limit  lab unit 
Systolic BP 90 150 mmHg 
Diastolic BP 40 90 mmHg 
Pulse rate 45 100 beats/min  
Respi[INVESTIGATOR_697]  8 22 breaths/min  
Oral temperature  95.9 
(35.5) <100.4 
(<38.0) F 
(C) 
 
  
DMID Protocol 16 -0118 Version 2.0 
Zoliflodacin  25 January 2018  
 ________________________________ ________________________________ ________________________________ ______  
 
 ________________________________ ________________________________ ________________________________ ______  
81 
  APPENDIX C: ADVERSE EVENTS TOXICITY GRAD ING 
CRITERIA  
ABBREVIATIONS : Abbreviations utilized in the Table:  
LLN = Lower Limit of Normal  
Req = Required  
IV = Intravenous  
Dec = Decreased  
ULN = Upper Limit of  
ESTIMATING SEVERITY GRADE  
For abnormalities NOT found elsewhere in the Toxicity Tables , use the scale below to 
estimate grade of severity:  
GRADE 1  Mild Events require minimal or no treatment ; do not interfere with the 
subject’s daily activities.  
GRADE 2  Moderate  Events result in a low  level of inconvenience or concern with 
therapeutic measures ; may cause some interference with 
functioning.  
GRADE [ADDRESS_961753]’s usual daily activity and may require 
systemic drug therapy or other treatment ; are usually 
incapacitati ng.  
SERIOUS OR LIFE -THREATENING AEs  
Clinical events considered to be serious or life -threatening include, but are not limited to:  
seizures, coma, tetany, diabetic ketoacidosis, disseminated intravascular coagulation, diffuse 
petechiae, paralysis, acute psychosis, and severe depression.  
COMMENTS REGARDING THE USE OF THESE TABLES  
• Standardized and commonly used toxicity tables (Division  of AIDS, National Cancer 
Institute [NCI] Common Toxicity Criteria [CTC], and World Health Organization 
[WHO]) have been adapted for use by [CONTACT_421237] (DMID) and modified to better meet the needs of subjects in DMID trials. 
• For parameters not included in the following Toxicity Tables, the site should refer to the 
“Guide for Estimating Severity Grade” located above.  
• Criteria are generally grouped by [CONTACT_6764].  
DMID Protocol [ADDRESS_961754] additional protocol specific gr ading criteria, which will supersede 
the use of these tables for specified criteria.  
Toxicity Grading Tables  
Clinical AEs Mild 
(Grade 1)  Moderate  
(Grade 2)  Severe 
(Grade 3)  Comments  
VITAL SIGNS  
Fever - °C 
 
Fever - °F 38.0-38.4 
 
100.4-101.1 38.5-38.9 
 
101.2-102.0 >38.9 
 
>102.[ADDRESS_961755] either 0C or 0F 
for inclusion  
Tachycardia - bpm 101-115 116-130 >[ADDRESS_961756]; for AE, 
measurements at least 
3 times with 2 
concordant results 
(Section 8.1.6) 
Bradycardia - bpm 50-54 OR 45 -50 if 
baseline <60   45-49 OR 40 -44 if 
baseline <60  <45 OR <40 if 
baseline <60  as above 
Hypertension 
(systolic) - mm Hg 141-150 151-160 >[ADDRESS_961757] ; for AE, 
measurements on 
same arm at least 3 
times with  2 
concordant results  
(Section 8.1.6) 
Hypertension 
(diastolic) - mm Hg 91-95 96-100 >100 As above 
 Hypotension 
(systolic) - mm Hg  85-89 80-84 <80 As above 
Tachypnea – breaths 
per min 23-25 26-30 >[ADDRESS_961758]; for AE, 
measurements at least 
3 times with 2 
concordant results 
(Section 8.1.6) 
Note: Isolated/individual abnormalities of vital signs would not be considered toward halting criteria. Abnormalities of vital 
signs should be described as “increase X” or “decrease X” (X = heart rate, blood pressure, respi[INVESTIGATOR_697], temperature) if 
asymptom atic, transient and not associated with a systemic or organ -specific disorder, and coded by [CONTACT_707790] (SOC) “Investigations.” These abnormalities should be graded per criteria in Appendix C , but not c onsidered in 
determining whether study stoppi[INVESTIGATOR_105308]. On the other hand, abnormalities of vital signs that are either 
DMID Protocol 16 -0118 Version 2.0 
Zoliflodacin  25 January 2018  
 ________________________________ ________________________________ ________________________________ ______  
 
 ________________________________ ________________________________ ________________________________ ______  
83 
  secondary to systemic or organ -specific clinical syndrome or primary disorders should be coded in the appropriate SOC (e .g., 
"cardiac disorders", respi[INVESTIGATOR_17744]", "immunological disorders", etc.). These abnormalities should be considered in 
determining whether stoppi[INVESTIGATOR_105308].  
 
Clinical AEs  Mild 
(Grade 1)  Moderate  
(Grade 2)  Severe 
(Grade 3)  Comments  
CARDIOVASCULAR  
Arrhythmia   
Asymptomatic or 
transient signs; no 
medical intervention 
required Recurrent and/or 
persistent signs; 
symptomatic 
medical 
intervention 
required  
Hemorrhage  Estimated blood loss 
<100 mL Estimated blood loss 
>100 mL; no 
transfusion required  Blood transfusion 
required  
RESPI[INVESTIGATOR_707759]; no 
treatment required   Persistent cough; 
treatment required  Interferes with 
daily activities   
Bronchospasm, 
Acute Transient 
bronchospasm; no 
treatment required; 
FEV1 71-80% of 
predicted peak flow  Requires treatment; 
normalizes with 
bronchodilator; 
FEV1 60-70% of 
predicted peak flow  
  No normalization 
with 
bronchodilator; 
FEV1 <60% of 
predicted peak 
flow   
Dyspnea   Does not interfere 
with usual and social 
activities Interferes with usual 
and social activities; 
no treatment  Prevents usual 
and social 
activities, OR 
requires treatment   
GASTROINTESTINAL   
Nausea  No interference with 
normal activity  Some interference 
with normal activity   Prevents daily 
activities  
Vomiting  No interference with 
activity, OR 1 -2 
epi[INVESTIGATOR_11630] a 24 -h 
period Some interference 
with activity, OR >2 
epi[INVESTIGATOR_11630] a 24 -h 
period Prevents daily 
activity, OR 
requires medical 
intervention    
DMID Protocol 16 -0118 Version 2.0 
Zoliflodacin  25 January 2018  
 ________________________________ ________________________________ ________________________________ ______  
 
 ________________________________ ________________________________ ________________________________ ______  
84 
  Clinical AEs  Mild 
(Grade 1)  Moderate  
(Grade 2)  Severe 
(Grade 3)  Comments  
Diarrhea  2-3 loose or watery 
stools in a 24 -h 
period 4-5 loose OR watery 
stools in a 24 -h 
period 6 or more loose 
or watery stools 
in a 24-h period, 
OR requires IV 
hydration OR 
requires medical 
intervention   
 
Oral Discomfort / 
Dysphagia   
Mild discomfort; no 
difficulty 
swallowing   
Some limits on eating 
/ drinking   
Eating / talking 
very limited; 
unable to swallow 
solid foods   
LOCAL IV CATHETER REACTION  
IV site reaction  Not Applicable  Erythema with 
associated symptoms 
(e.g., edema, pain, 
induration, phlebitis)  Ulceration or 
necrosis; severe 
tissue damage; 
operative 
intervention 
indicated  
SYSTEMIC REACTIONS  
Anaphylaxis **  
 
 -- -- Symptomatic 
bronchospasm, 
with or without 
urticaria; 
parenteral 
intervention 
indicated; allergy -
related 
edema or 
angioedema;  
hypotension   
**Definition : A disorder characterized by [CONTACT_210938] -like substances from mast cells, causing a hypersensitivity immune response. Clinically, it presents 
with breathing difficulty, dizziness, hypotension, cyanosis and loss of consciousness and may lead to death.  
Allergic Reaction  Pruritus without rash  Localized urticaria 
OR requires oral 
therapy Generalized 
urticaria; 
angioedema OR 
anaphylaxis OR  
requires 
epi[INVESTIGATOR_707760] 16 -0118 Version 2.0 
Zoliflodacin  25 January 2018  
 ________________________________ ________________________________ ________________________________ ______  
 
 ________________________________ ________________________________ ________________________________ ______  
85 
  Clinical AEs  Mild 
(Grade 1)  Moderate  
(Grade 2)  Severe 
(Grade 3)  Comments  
Hypersensitivity 
(including drug 
fever) Transient flushing or 
rash; temperature 
38.0-38.4 °C (100.4 -
101.1°F) Rash; flushing; 
urticaria; dyspnea; 
temperature 38.5  - 
38.9°C (101.2 – 
102.0°F) Symptomatic 
bronchospasm 
with or without 
urticaria; 
parenteral 
medication 
indicated;  
allergy-related 
edema or 
angioedema; 
hypotension ; 
temperature 
>38.9°C 
(>102.0°F)  
  
Headache  No interference with 
activity Repeated use of non -
narcotic pain reliever 
for more than 24 h 
OR some interference 
with activity   Significant; any 
use of narcotic 
pain reliever OR 
prevents daily 
activity OR 
requires triptans   
Fatigue  No interference with 
activity Some interference 
with activity  Significant; 
prevents daily 
activity   
Myalgia No interference with 
activity Some interference 
with activity  Significant; 
prevents daily 
activity   
SKIN 
Mucocutaneous  Erythema, pruritus Diffuse, maculo -
papular rash, dry 
desquamation  Vesiculation  OR 
moist 
desquamation OR 
ulceration   
Pruritus No or minimal 
interference with 
usual social and 
functional activities  Greater than minimal 
interference with 
usual social and 
functional activities  Inability to 
perform usual 
social and 
functional daily 
activities  
ALL OTHER CONDITIONS  
Illness or clinical AE 
(as defined according 
to applicable 
regulations)  No interference with 
activity Some interference 
with activity but not 
requiring medical 
intervention  Prevents daily 
activity and 
requires medical 
intervention   
 
DMID Protocol 16 -0118 Version 2.0 
Zoliflodacin  25 January 2018  
 ________________________________ ________________________________ ________________________________ ______  
 
 ________________________________ ________________________________ ________________________________ ______  
86 
  Laboratory AEs  Mild 
(Grade 1)  Moderate  
(Grade 2)  Severe 
(Grade 3)  
Blood, serum, or plasma *  
Sodium decrease – mmol/L 130 –132 125 –130 <125 
Sodium increase – mmol/L 148 – 149 150 – 153 ≥154 
Potassium increase – mmol/L 5.3 – 6.0 6.1 – 6.4 ≥6.5 
Potassium decrease – mmol/L 3.0 – 3.3 2.5 – 2.9 <2.5 
Bicarbonate  (CO2) increase  – mmol/L 32 - 34 35 – 36 >36 
Bicarbonate  (CO2) decrease – mmol/L 18 -- 20 14 - 17 <14 
Glucose decrease, fasting – mg/dL 50 – 73 45 – 49 <45 
Glucose increase, fasting – mg/dL 107– 125 126 - 249 ≥250 
Glucose increase, non-fasting – mg/dL 107- 160 161 - 249 ≥250 
Blood urea nitrogen – mg/dL 21 – 26 27 – 31 >31 
Creatinine increase  – mg/dL 1.4 – 1.7 1.8 – 2.3 >2.3 
Calcium decrease – mg/dL 7.8 –8.0 7.0 – 7.7 <7.0 
Calcium increase – mg/dL 11.0 – 11.4 11.5 – 12.4 ≥12.5 
Phosphorous increase – mg/dL 4.8 – 5.0 5.1 – 5.5 >5.5 
Phosphorous decrease – mg/dL 2.0 – 2.4 1.4 – 1.9 <1.4 
Total protein decrease – g/dL 5.2 – 6.0 4.8 – 5.1 <4.8 
Albumin decrease – g/dL 2.8 – 3.4 2.5 – 2.7 <2.[ADDRESS_961759] increase – U/L 43 – 104 105 – 209 ≥210 
ALT increase, male – U/L 73 – 179 180 – 359 ≥360 
ALT increase, female – U/L 45 – 109 110 – 219 ≥220 
Alkaline phosphatase increase – U/L 151 – 240 241 – 360 >360 
Total bilirubin (serum)  increase – mg/dL 
(with other LFTs in the normal range)  1.4 – 2.0 2.1 – 2.5 >2.5 
Total bilirubin (serum)  increase – mg/dL 
(accompanied by a >[ADDRESS_961760])** 1.4 – 1.6 1.7 – 2.0 >2.0 
Hemoglobin  decrease, female – g/dL 11.0 – 11.5 9.5 – 10.9 < 9.5 
Hemoglobin  decrease, male – g/dL 12.0 –13.5 10.0 – 11.9 <10.0 
WBC increase – cell/mm3 11,000 – 15,000 15,001 – 20,000 >20,000 
WBC decrease – cell/mm3 2,500 –3,500 1,500 – 2,499 <1,500 
Neutrophils decrease – cell/mm3 1,200 – 1,399 1,000 – 1,199 <1,000 
Lymphocytes decrease – cell/mm3 750 – 999 500 – 749 <500 
Monocytes increase – cell/mm3 1,101 – 2,000 2,001– 3000 >3,000 
Eosinophils increase – cell/mm3 500 – 750 751 – 1,500 >1,500 
Basophils increase – cell/mm3 201 – 500 501 – 800 >800 
Platelets decrease – cell/mm3 120,000 – 125,000 100,000 – 
<120,000 <100,000 
DMID Protocol 16 -0118 Version 2.0 
Zoliflodacin  25 January 2018  
 ________________________________ ________________________________ ________________________________ ______  
 
 ________________________________ ________________________________ ________________________________ ______  
87 
  Laboratory AEs  Mild 
(Grade 1)  Moderate  
(Grade 2)  Severe 
(Grade 3)  
Urine* 
Protein 1+ 2+ >2+ 
Glucose 1+ 2+ >2+ 
Blood (dipstick)  1+ 2+ >2+ 
Blood (microscopic) - RBCs per HPF  
6-10 11-50 >50 and/or gross 
blood 
WBC (microscopic) – WBC per HPF  5-10 11-50 >50 
Bacteria (microscopic)  few moderate many 
* Institutional normal reference ranges and allowable ranges at screening are provided in Appendix B . 
**ALT, males: >216 U/mL; ALT, females: >132 U/mL; AST, male or female: >126 U/mL)  
Note 1: If a subject was accepted into the trial with a laboratory value of an analyte that overlaps with values used for grading 
Grade 1 (mild) laboratory abnormalities, an AE will be reported if the on -study value of the same analyte i s different (worse) 
from the baseline.  
Note 2: Safety laboratory results that are abnormal according to the local laboratory reference range, but not considered a 
Grade 1 abnormality, will be evaluated by [CONTACT_707791] 1 ab normality if clinically significant. If 
not clinically significant, these will not be considered laboratory AEs and will thus not be graded, but will be recorded in the 
source document and followed -up clinically at the discretion of the study site clinicia n.  
Note 3: Other laboratory parameters performed and reported as parted of the complete blood count, metabolic panel and 
urinalysis will be evaluated by [CONTACT_5989], recorded in the source document, and reported as laboratory AEs if clini cally 
significant, and graded according to the criteria in Section 9.2.1. 
Note 4: If US by [CONTACT_92223], a microscopic UA will be performed and the results will supersede the results of the 
dipstick UA.  
Note 5: Menstruating females with a positive urine dipstick or microscopic UA may be retested following cessation of menses.  
  
DMID Protocol 16 -0118 Version 2.0 
Zoliflodacin  25 January 2018  
 ________________________________ ________________________________ ________________________________ ______  
 
 ________________________________ ________________________________ ________________________________ ______  
88 
   
ECG interval abnormality  Grade 1 Grade 2 Grade 3 
QT/QTc interval (Fridericia’s correction)  
prolonged  (msec) Asymptomatic, QTc 
450-479 msec, OR 
increase in interval 
<30 msec above 
baseline 
 Asymptomatic, 
QTc 480-499 
msec OR increase 
in interval 30 -59 
msec above 
baseline Asymptomatic, QTc 
≥500 msec OR 
increase in interval 
≥60 msec above 
baseline 
PR interval prolonged - sec 0.21-0.25 sec >0.25 sec  Type II 2nd degree 
AV block OR 
ventricular pause 
>3.0 sec 
Note: The events will be coded as SAE if there are life -threatening associated symptoms or signs (arrhythmia, CHF, hypotension, 
syncope, torsade’s de pointes, etc.)  
Note: If a male subject was accepted into the trial with a QT/QTc value that overlaps with values used for grading Grade 1 
(mild) QT/QTc prolongation, an AE will be reported if the on -study value of the QT/QTc is higher than the baseline.
DMID Protocol 16 -0118 Version 2.0 
Zoliflodacin  25 January 2018  
 ________________________________ ________________________________ ________________________________ ________________________________ _____________   
 
 ________________________________ ________________________________ ________________________________ ________________________________ _____________   
  89 
 APPENDIX D: BLOOD VO LUME WITHDRAWN DURIN G THE TRIAL 
Laboratory Samples and Estimated Total Blood Volume (mL)  
 
Study visit  SCREENING  CHECK-
IN INPATIENT  PERIOD  FINAL 
Total volume  Early term visit  
Study Day -21 to -2 -1 1 2 3 4  
8 (±2) 
 
HEMATOLOGY  1 4 4    4  12 4 
CHEMISTRY and  serum β-
HCG, FSH, HIV, HBsAg, 
HCV 1 5 5    5  15 5 
PK 2   54 12 6 6  78 6 
Total volume/visit 9 9 54 12 6 15 0 - 15 
Cumulative total volume 9 18 72 84 90 105 105 105  
 
1 Clinical blood tests are drawn  at Screening  Visit, on Day-1, and on Day 4, or ET.  
2 PK serum samples are drawn on Day 1: 30 min before dosing and at 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 h after dosing , or ET. 
 